Core Highlights of the Week

Top Movers

Exhibit 1. Top Healthcare/Biotechnology Movers for the Trailing Four-Week & YTD Periods



Source: Leede Financial, Refinitiv

Updates From Our Coverage Universe

- **Starting 2026 With An Investment Thesis Summary Of Our Theratechnologies-Less (& Soon-To-Be-Quipt Home Medical-Less) Coverage Universe.** We thought that as an initial exercise in resuming publication of our Healthcare Weekly, we would summarize our current healthcare coverage universe in a bullet-point fashion, emphasizing key metrics on which our various investment theses are focused & then conclude with a valuation summary along with details where appropriate of pending milestones in support of that investment thesis.

  As we have emphasized in many recent Healthcare Weeklies in F2025, there is a sizable proportion of healthcare equities that are either formally covered by us or are coverage-adjacent that generated correspondingly sizable returns over a trailing one-year or two-year period. We quantify that statement as we always do in tabular form at the end of this document. With that as a lead-in, our coverage universe as of this writing, in no particular order, is as follows:

  - **CareRx (CRRX-T, Buy, PT C$4.75).** This long-term care-focused pharmacy services provider has for several quarters been the largest provider of such services in Canada, achieving that status through acquisition of peer firms ON-based Medical Pharmacies Group (in Apr/21) & other significant but smaller transactions before that (including BC-based CareRx Enterprises acquired in Sept/16 on which the firm now bases its corporate brand & originally establishing its footprint in this healthcare services niche by acquiring ON-based Classic Care back in Nov/11).

    - Debt burden that was long a barrier to share price augmentation is no longer a burden, at least as defined by any EBITDA-based financial ratios that saw the firm exit FQ325 with a debt-to-quarterly EBITDA run-rate ratio of 1.3x & an EBITDA-to-interest coverage ratio of 5.2x. Mitigating financial risk to this degree allows us to focus on operating fundamentals for the firm & its macroenvironment in the Canadian long-term care pharmaceuticals distribution industry in which it competes.

Douglas W. Loe, PhD MBA | Managing Director & Analyst | dloe@leede.ca | 416.365.9924
Owen Jones, M.HSc. | Associate | 647.973.6664

- Our model does not assume any sizable acquisitions during our F2026-to-F2027 forecast period but organic EBITDA growth through new LTC Rx contract wins & ongoing cost containment is expected by us to stabilize EBITDA margin at or above FQ325 level of 9.0%. CareRx's main competitors in the Canadian LTC Rx universe are probably Loblaw/Shoppers Drug Mart/Medisystem (L-T, NR) & Sobeys Continuing Care/National Pharmacy Group (private), but neither firm tends to publish details on LTC Rx-specific activities for us to review.

Exhibit 2. Income Statement & Financial Forecast Data for CareRx

Year-end December 31 (C$000, except EPS)	2017A	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E	2026E	2027E
Physio/Rehab/Assessment	0	0	0	0	0	0	0	0	0	0	0
LTC Pharmacy Services	124,453	125,352	125,795	162,196	262,630	381,727	370,746	366,714	368,953	384,280	392,452
Surgical & Medical Centers	44,514	43,679	0	0	0	0	0	0	0	0	0
Total revenue	**$168,967**	**$169,031**	**$125,795**	**$162,196**	**$262,630**	**$381,727**	**$370,746**	**$366,714**	**$368,953**	**$384,280**	**$392,452**
Revenue growth (%)	*0%*	*0%*	*($26%)*	*29%*	*62%*	*45%*	*($3%)*	*($1%)*	*1%*	*4%*	*2%*
EBITDA, pharmacy	$17,014	$9,844	$15,137	$17,398	$32,705	$36,072	$34,673	$38,297	$39,979	$42,033	$43,320
EBITDA margin, pharmacy (%)	*13.7%*	*7.9%*	*12.0%*	*10.7%*	*12.5%*	*9.4%*	*9.4%*	*10.4%*	*10.8%*	*10.9%*	*11.0%*
EBITDA, surgery	$6,180	$6,596	$0	$0	$0	$0	$0	$0	$0	$0	$0
EBITDA margin, surgery (%)	*13.9%*	*15.1%*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*
EBITDA, other divisions less corporate costs	($5,681)	($5,570)	($5,658)	($4,622)	($9,375)	($3,805)	($6,000)	($8,000)	($7,991)	($8,070)	($8,241)
EBITDA	**$17,513**	**$10,870**	**$9,479**	**$12,776**	**$23,331**	**$32,267**	**$28,673**	**$30,297**	**$31,989**	**$33,963**	**$35,078**
EBITDA growth (%)	*13.2%*	*(37.9%)*	*(12.8%)*	*34.8%*	*82.6%*	*38.3%*	*(11.1%)*	*5.7%*	*5.6%*	*6.2%*	*3.3%*
EBITDA margin (%)	*10.4%*	*6.4%*	*7.5%*	*7.9%*	*8.9%*	*8.5%*	*7.7%*	*8.3%*	*8.7%*	*8.8%*	*8.9%*
Net income	$520	($34,388)	($45,677)	($18,262)	($22,730)	($34,353)	($5,405)	($4,502)	$2,317	$1,854	$2,803
Adj. net inc	($782)	($6,167)	($35,642)	($7,242)	($11,008)	($5,378)	($1,597)	($1,696)	$3,848	$2,374	$3,323
EPS (basic)	**($0.08)**	**($0.59)**	**($3.11)**	**($0.33)**	**($0.27)**	**($0.11)**	**($0.03)**	**($0.03)**	**$0.06**	**$0.04**	**$0.05**
EPS (fd)	($0.07)	($0.58)	($2.92)	($0.32)	($0.20)	($0.09)	($0.02)	($0.02)	$0.06	$0.04	$0.05
S/O, basic	*10,256*	*10,436*	*11,475*	*21,918*	*40,921*	*48,191*	*58,168*	*60,562*	*62,949*	*62,981*	*62,981*
S/O, fd (inc convert debt)	*10,528*	*10,654*	*12,200*	*22,723*	*56,047*	*61,819*	*71,517*	*72,110*	*65,460*	*65,642*	*65,642*
P/E (basic)	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*62.2x*	*NA*	*NA*
EV/EBITDA	*15.4x*	*24.7x*	*28.4x*	*21.0x*	*11.5x*	*8.3x*	*9.4x*	*8.9x*	*8.4x*	*7.9x*	*7.7x*

Source: CareRx financial filings; Leede Financial

- Our CRRX valuation is based on 10x EV-to-EBITDA, a calculation that includes our F2026 EBITDA forecast of $34.0M (which we consider to be a base-case projection when considering that FQ325 EBITDA was $8.3M & thus close to that value on a run-rate basis), pro forma cash of $14.8M (FQ325 cash of $16.0M, less $0.02/shr dividend that was paid a few weeks after quarter-end), total debt of $44.3M & fd S/O of 65.0M. At current levels, our PT corresponds to a one-year return of 25%. Excluding dividend yield that is a recent manifestation of CareRx's financial profile, CRRX generated T12M return of 80% &T24M return of 113%.

Exhibit 3. Valuation Scenarios for CareRx

EV/EBITDA multiple, F2026	4x	6x	8x	10x	12x	14x
Implied share price[1]	$1.69	$2.77	$3.84	$4.92	$6.00	$7.08
One-year CRRX target price [1,2]				**$4.92**		

[1] *Based on F2026 EBITDA of $34.0M; 63.0M basic S/O, 65.0M fd S/O*

[2] *Pro forma cash of $14.8M (FQ325 cash of $16.0M, less $0.02/shr dividend paid in mid-Oct/25; total adjusted debt of $44.3M*

Source: CareRx financial filings; Leede Financial

- **Extendicare (EXE-T, Buy, PT C$22.75).** ON-based eldercare services firm that was historically focused on nursing home-home healthcare-assisted living-consulting/group purchasing operations makes a sizable shift toward emphasizing its home healthcare infrastructure with two major acquisitions in recent months, first by acquiring peer firm ON/NS-based Closing The Gap Healthcare Group in May/25 (for which T12M revenue was $84.2M, but with up-to-

$11.0M in additional annual revenue expected as part of an earn-out stipulation next year) & later acquiring ON-based CBI Home Health in Nov/25 (for which T12M revenue was $477.9M).

- Taking these two acquisitions together & assuming as our model does that T12M revenue is a reasonable base-case scenario for F2026/27 revenue contribution under Extendicare's stewardship (which our model does), Extendicare's home healthcare operations now are expected in our model to leap from annual home healthcare revenue of $686.6M & $714.4M in F2026/27 respectively (our current forecast for Extendicare's legacy ParaMed operations) to $1.25B & $1.30B (the sum of our ParaMed-Revera-CBI-Closing The Gap forecasts in Exhibit 4), respectively.

Exhibit 4. Income Statement & Financial Forecast Data for Extendicare

Year-end December 31 *(C$M, exc share-based data)*	2017A	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E	2026E	2027E	2028E
Revenue, SNFs	$616.9	$632.5	$643.8	$715.6	$771.2	$767.1	$788.1	$827.4	$898.5	$1,038.1	$1,075.2	$1,113.9
Revenue, ParaMed (home health)	$220.7	$222.3	$214.0	$188.2	$217.7	$228.9	$276.3	$552.4	$650.0	$686.6	$714.4	$743.5
Revenue, Revera (home health)	$215.0	$209.0	$209.0	$180.0	$192.9	$192.8	$192.8	$0.0	$0.0	$0.0	$0.0	$0.0
Revenue, CBI (home health)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$59.7	$477.9	$490.0	$509.9
Revenue, Closing The Gap (home)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$42.3	$87.2	$90.7	$94.4
Revenue, Assist liv	$20.7	$33.4	$41.3	$47.8	$49.8	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Revenue, other Cdn ops	$18.8	$22.3	$23.9	$26.8	$27.8	$32.8	$47.8	$72.7	$67.6	$64.4	$67.0	$69.8
Revenue, US ops	$5.3	$0.4	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Consolidated revenue	$1,097.3	$1,120.0	$1,132.0	$1,158.3	$1,259.3	$1,221.6	$1,305.0	$1,452.6	$1,718.2	$2,354.2	$2,437.4	$2,531.4
Rev growth (%)	*2.7%*	*2.1%*	*1.1%*	*2.3%*	*8.7%*	*(3.0%)*	*6.8%*	*11.3%*	*18.3%*	*37.0%*	*3.5%*	*3.9%*
EBITDA	**$97.6**	**$94.2**	**$91.1**	**$41.7**	**$77.7**	**$55.8**	**$95.2**	**$142.7**	**$176.1**	**$241.1**	**$254.7**	**$269.8**
EBITDA margin (%)	*8.9%*	*8.4%*	*8.0%*	*3.6%*	*6.2%*	*4.6%*	*7.3%*	*9.8%*	*10.2%*	*10.2%*	*10.5%*	*10.7%*
EBITDA growth (%)	*5.0%*	*(3.4%)*	*(3.3%)*	*(54.2%)*	*86.3%*	*(28.1%)*	*70.5%*	*50.0%*	*23.4%*	*36.9%*	*5.7%*	*5.9%*
Non-oper exp (inc D&A)	*$27.0*	*$34.1*	*$35.7*	*$39.7*	*$36.2*	*$27.4*	*$38.9*	*$28.1*	*$33.5*	*$44.0*	*$45.7*	*$47.5*
Interest expense	*$28.1*	*$27.6*	*$28.7*	*$28.5*	*$27.3*	*$20.6*	*$20.6*	*$20.1*	*$22.6*	*$35.4*	*$34.2*	*$33.7*
Tax expense	*$10.9*	*$4.2*	*$7.2*	*$16.3*	*$6.5*	*$0.0*	*$10.8*	*$24.7*	*$31.4*	*$40.0*	*$43.3*	*$46.7*
Adjusted EPS (basic)	**$0.36**	**$0.09**	**$0.19**	**$0.48**	**$0.08**	**($0.05)**	**$0.40**	**$0.88**	**$1.09**	**$1.27**	**$1.38**	**$1.48**
Adjusted AFFO	**$0.66**	**$0.65**	**$0.59**	**$0.88**	**$0.60**	**$0.28**	**$0.73**	**$1.09**	**$1.25**	**$1.83**	**$1.96**	**$1.98**
Dividend per share	$0.48	$0.48	$0.48	$0.48	$0.48	$0.48	$0.48	$0.48	$0.50	$0.50	$0.50	$1.50
Implied payout ratio (%)	*73%*	*73%*	*81%*	*54%*	*80%*	*169%*	*66%*	*44%*	*40%*	*27%*	*25%*	*76%*
P/E ratio	*60.4x*	*235.8x*	*112.7x*	*44.7x*	*253.8x*	*(420.7x)*	*53.4x*	*24.6x*	*19.8x*	*17.0x*	*15.7x*	*14.5x*
EV-to-EBITDA	*24.1x*	*24.9x*	*25.8x*	*56.3x*	*30.2x*	*42.1x*	*24.7x*	*16.5x*	*13.3x*	*9.7x*	*9.2x*	*8.7x*
Price/AFFO	*32.7x*	*33.0x*	*36.5x*	*24.4x*	*36.0x*	*76.0x*	*29.6x*	*19.9x*	*17.2x*	*11.8x*	*11.0x*	*10.9x*

Source: Extendicare financial filings; Leede Financial

- Our model assumes that new acquisitions will not compress EBITDA margin for home healthcare, holding firm at our previous forecast of 13.4% & 13.7% in F2026/27 (nursing home operations are projected by us to be slightly lower at 11.6%-11.7% in both years, with Extendicare Assist consulting services/group purchasing operations expected to be substantially higher at 54.9% in both years, though with far lower scale of EBITDA contribution on an absolute basis).

- We have long endorsed investment in home healthcare as a way to cost-effectively provide health services to elderly patients & we are thus encouraged by Extendicare's agreement on this thesis. The firm experienced substantial margin challenges during the F2020-to-F2022 pandemic era from which it has emerged scarred but not injured & our model assumes that the firm can sustain its leadership in eldercare services going forward.

- Our valuation continues to be based on multiples of our F2027 AFFO & EBITDA forecasts of $1.96/shr & $254.7M, respectively, with our EV calculation incorporating pro forma cash of $52.8M (FQ325 cash of $166.8M, less presumed cash outlay to partially fund the CBI acquisition) & total debt of $602.0M (FQ325 debt of $337.5M, plus

new debt to partially fund CBI's acquisition), with revised basic S/O of 94.5M giving effect to the equity offering that Extendicare consummated last quarter to partially fund the CBI transaction.

- As we have emphasized in prior Healthcare Weeklies, the Canadian eldercare services sector generated substantial returns in recent quarters & this manifestation is not unique to Extendicare though Extendicare has unambiguously outperformed its more real estate-focused peers Sienna Senior Living (SIA-T, NR) & Chartwell Retirement Residence (CSH.U-T, NR) on trailing share price appreciation. Our EXE PT corresponds to a one-year total return, including 2.5% dividend yield, of 7.9%, clearly migrating into Hold territory after substantial returns achieved during FQ425 alone (T3M return of 45%) but we believe that newly-achieved industry stability, when taken together with recent margin improvements notably in home healthcare, justifies our sustained positive view on share price trajectory. The stock generated T12M & T24M returns of 110% & 201%, respectively.

Exhibit 5. Valuation Scenarios for Extendicare

AFFO multiple, F2027	5x	7x	9x	11x	13x	15x
Implied unit price [1]	$9.81	$13.74	$17.67	**$21.59**	$25.52	$29.44
EV-to-EBITDA multiple, F2027	**5x**	**7x**	**9x**	**11x**	**13x**	**15x**
Implied unit price [1,2]	$7.67	$13.06	$18.46	**$23.85**	$29.25	$34.64
One-year EXE target price [1,2]				***$22.72***		
Implied dividend yield (%)				***2.2%***		
Current dividend yield (%)				*2.5%*		

[1] Based on F2027 EBITDA forecast of $254.7M & F2027 AFFO forecast of $1.96/shr, both revised to incorporate impact from the Closing the Gap & CBI Home Health acquisitions

[2] EV includes pro forma cash of $52.8M (FQ325 cash of $166.8M, less cash outlay for CBI acquisiton); pro forma LT debt of $602.0M (FQ325 LT debt of $337.5M, plus $264.5M in new debt to partially fund CBI Home Health acquisition; revised basic S/O of 94.5M

Source: Extendicare financial filings; Leede Financial

- **Medical Facilities (DR-T, Hold, PT C$15.50).** Our Hold recommendation on SD-based specialty surgical hospital consolidator & operator Medical Facilities is purely a valuation call, with our investment thesis still assuming that the firm's dividend policy confers little-to-no financial risk on the stock – in FQ325 specifically, payout ratio for quarterly dividend of C$0.089/shr was 35.0% when compared to distributable cash generated in the quarter of US$3.4M. This level of distributable cash generation was sustained even while the firm divested one of its profitable SD-based surgical hospitals in SD-based Black Hills Surgery Center back in Nov/24.

  - The firm tends to generate seasonally strong financial data in FQ4 though the magnitude by which seasonal strength has manifested itself in recent years has softened & we thus expect FQ425 financial data when reported to further support dividend policy & thus support DR attractiveness. We see no evidence in recent hospital-specific financial data to assume that any surgical hospital that Medical Facilities oversees in SD-OK-AR will infuse any new business risk into the firm. Even OK-based Oklahoma Spine Hospital for which operating margins have been sporadically soft in recent quarters has generated average margin that is solidly into double-digit territory & frequently was not during the F2019-to-F2024 period.

  - Medical Facilities essentially derives EBITDA & distributable cash from three facilities – Sioux Falls Surgical Hospital, Arkansas Surgical Hospital & the aforementioned spine surgery facility in OK – for which we project facility-specific FQ425 revenue/EBIT margin of US$45.2M/21.3%, US$24.6M/21.2% & US$19.9M/8.1% respectively, with minimal contribution from ambulatory surgical center (ASC) operations in CA of US$2.2M/10.0% having correspondingly minimal impact on distributable cash, even if data outperform our forecasts.

Exhibit 6. Income Statement & Financial Forecast Data for Medical Facilities

Year-end December 31 (US$000, except EPS)	2016A	2017A	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E	2026E	2027E
Total revenue	**$339,473**	**$385,329**	**$431,602**	**$398,103**	**$389,862**	**$411,732**	**$414,389**	**$445,582**	**$410,083**	**$336,775**	**$339,955**	**$343,169**
Revenue growth (%)	*9%*	*14%*	*12%*	*(8%)*	*(2%)*	*6%*	*1%*	*8%*	*(8%)*	*(18%)*	*1%*	*1%*
EBITDA	$90,706	$94,647	$99,018	$96,248	$95,682	$104,127	$72,251	$88,646	$84,797	$70,720	$73,407	$74,102
EBITDA growth (%)	*(9%)*	*4%*	*5%*	*(3%)*	*(1%)*	*9%*	*(31%)*	*23%*	*(4%)*	*(17%)*	*4%*	*1%*
EBITDA margin (%)	*27%*	*25%*	*23%*	*24%*	*25%*	*25%*	*17%*	*19.9%*	*20.7%*	*21.0%*	*21.6%*	*21.6%*
Consolidated net income	$39,689	$46,579	$51,549	$59,677	$39,259	$46,618	$12,869	$43,999	$68,554	$45,160	$37,876	$39,104
Net inc, minority interest	$47,440	$25,942	$30,622	$25,422	$37,520	$30,993	$16,700	$21,145	$30,348	$15,458	$9,469	$9,776
Net inc, common share hlrs	($7,751)	$20,637	$20,927	$34,255	($1,837)	$15,625	($3,831)	$22,854	$38,206	$29,702	$28,407	$29,328
Consolidated EPS	$1.28	$1.50	$1.66	$1.92	$1.26	$1.50	$0.45	$1.75	$2.89	$2.41	$2.06	$2.13
EPS, minority interest	$1.53	$0.84	$0.99	$0.82	$1.21	$1.00	$0.58	$0.84	$1.28	$0.82	$0.52	$0.53
EPS, common share hlrs	($0.25)	$0.67	$0.68	$1.10	($0.06)	$0.50	($0.13)	$0.91	$1.61	$1.58	$1.55	$1.60
Consolidated AFFO/unit	$1.23	$1.29	$1.22	$0.66	$0.96	$0.96	$0.69	$0.89	$1.03	$1.26	$1.62	$1.65
Consolidated AFFO/unit (C$)	$1.64	$1.67	$1.60	$0.87	$1.28	$1.21	$0.89	$1.21	$1.41	$1.78	$1.66	$1.58
Adj AFFO/unit (C$; share hldrs)	$0.86	$0.88	$0.86	$0.45	$0.67	$0.64	$0.47	$0.63	$0.75	$0.94	$0.88	$0.84
Payout per IPS unit (C$)	$1.13	$1.13	$1.13	$0.98	$0.28	$0.29	$0.33	$0.33	$0.34	$0.36	$0.36	$0.36
Payout ratio (%)	*69%*	*68%*	*70%*	*113%*	*22%*	*24%*	*37%*	*27%*	*24%*	*20%*	*22%*	*23%*
Share of financial data ascribed to common shareholders												
Adj EBITDA (US$000) [1]	**$47,893**	**$50,071**	**$53,127**	**$49,999**	**$50,213**	**$55,235**	**$37,905**	**$46,507**	**$44,877**	**$37,345**	**$39,030**	**$39,284**
Adj EPS (US$) [1,2]	**($0.25)**	**$0.67**	**$0.68**	**$1.10**	**($0.06)**	**$0.50**	**($0.13)**	**$0.91**	**$1.61**	**$1.58**	**$1.55**	**$1.60**
Adj AFFO (US$) [1]	**$0.65**	**$0.68**	**$0.65**	**$0.34**	**$0.50**	**$0.51**	**$0.36**	**$0.47**	**$0.54**	**$0.67**	**$0.86**	**$0.88**
Proportion of facilities owned by common shareholders	*52.8%*	*52.9%*	*53.7%*	*51.9%*	*52.5%*	*53.0%*	*52.5%*	*52.5%*	*52.9%*	*52.8%*	*53.2%*	*53.0%*
Adjusted AFFO multiple	*13.0x*	*12.4x*	*13.0x*	*24.7x*	*16.8x*	*16.6x*	*23.5x*	*18.0x*	*15.6x*	*12.7x*	*9.9x*	*9.7x*
Price-to-adj EPS multiple	*NA*	*17.6x*	*17.3x*	*10.6x*	*NA*	*23.2x*	*NA*	*12.9x*	*7.3x*	*7.4x*	*7.6x*	*7.3x*
Adj EV/EBITDA multiple	*5.7x*	*5.5x*	*5.2x*	*5.5x*	*5.5x*	*5.0x*	*7.3x*	*5.9x*	*6.1x*	*7.4x*	*7.0x*	*7.0x*

[1] *Adjusted for proportion of financial data ascribed to common shareholders and not to non-controlling interests*

Source: Medical Facilities financial filings; Leede Financial

- As before, our DR valuation is based on multiples ascribed to our adjusted F2026 AFFO & EBITDA forecasts of US$0.86/shr & US$39.0M, with the term 'adjusted' in this context meaning that we apply multiples to the proportion of AFFO/EBITDA attributable to common shareholders (about 53%) & not to that proportion owned by physician owners of the relevant facilities contributing to those financial metrics. Our EV calculation incorporates FQ325 balance sheet data (cash of US$46.8M, total debt of US$32.6M) & basic S/O of 18.3M.

Exhibit 5. Valuation Scenarios for Medical Facilities

AFFO multiple (F2026)	5x	7x	9x	10x	11x	13x	15x
Implied unit price [1,2]	$4.29	$6.01	$7.73	**$8.59**	$9.45	$11.17	$12.88
EV/EBITDA multiple (F2026)	**2.0x**	**4.0x**	**5.0x**	**6.0x**	**7.0x**	**9.0x**	**11.0x**
Implied share price ($) [1,2]	$5.03	$9.29	$11.42	**$13.54**	$15.67	$19.93	$24.18
One-year Medical Facilities target price (US$)				**$11.07**			
One-year Medical Facilities target price (C$) [2,3]				**$15.29**			

[1] *Based on adjusted F2026 EBITDA of $39.0M & F2026 adjusted AFFO of $0.86/shr; EV incorporates FQ325 debt of $32.6M, S/O of 18.3M & pro forma cash (including Black Hills proceeds & cash outlay for FQ125 share buyback) of $46.8M*

[2] *Consolidated F2026 financial forecasts including non-controlling interest & after adjusting for physician ownership - EBITDA of $73.4M & F2025 AFFO of $1.62/shr*

[3] *Based on a USD to CAD conversion rate of 1.38x*

Source: Medical Facilities financial filings; Leede Financial

- We remind DR followers that the firm has been aggressively repurchasing shares that if sustained at recent pace could be well on the way to taking the firm private by its existing shareholder base. Indeed, cumulative share repurchasing activity since FQ421 has deployed US$123.0M in available cash for that purpose, bringing basic S/O down from 31.1M in FQ321 to current level. Expectations that Medical Facilities could stabilize share price by deploying operating cash flow to capital structure revision could be an independent valuation driver for the stock, as it has been in prior periods.

- Though we are maintaining our Hold rating on DR, we observe that the stock did achieve a T24M return of 82.2% & thus over a longer-term time horizon that includes several months during F2024 that we ascribed a Buy rating to the stock. DR shares achieved a more modest T12M return on share price appreciation alone of 4.5% (or total return of 6.7%, including dividend yield) that corresponds more suitably to our rating hierarchy for which a Hold rating applies.

- **K-Bro Linen (KBL-T, Buy, PT C$46.00).** AB-based hospital/hospitality-focused linen/laundry processing firm K-Bro Linen is expected by us to sustain conventional operations throughout our forecast period, absent any extraordinary epidemiological elements that compressed hospitality-focused operations during F2020/21. Though our model does not overtly assume any acquisitive growth, our investment thesis does cater to the possibility that the firm could expand scale of operations both domestically & internationally, especially in the UK where the firm consummated two sizable acquisitions in FQ417 & Jun/25 as we summarize below.

Exhibit 7. Income Statement & Financial Forecast Data for K-Bro Linen

Year-end December 31											
(C$000, except EPS)	2017A	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E	2026E	2027E
Healthcare revenue	$116,948	$128,933	$132,620	$144,715	$159,938	$167,239	$177,838	$189,400	$198,560	$202,531	$206,582
Hospitality revenue	$48,883	$50,956	$54,004	$21,967	$23,135	$44,796	$63,291	$75,022	$79,098	$81,471	$83,916
International revenue (UK)	$4,728	$59,645	$65,786	$29,909	$40,919	$64,588	$79,755	$109,187	$216,222	$291,429	$297,257
Total revenue	**$170,559**	**$239,534**	**$252,410**	**$196,591**	**$223,992**	**$276,623**	**$320,884**	**$373,609**	**$493,881**	**$575,431**	**$587,755**
Revenue growth (%)	*7.2%*	*40.4%*	*5.4%*	*(22.1%)*	*13.9%*	*23.5%*	*16.0%*	*16.4%*	*32.2%*	*16.5%*	*2.1%*
EBITDA	**$24,021**	**$29,517**	**$47,565**	**$43,755**	**$42,791**	**$36,492**	**$56,806**	**$69,020**	**$86,078**	**$99,173**	**$102,836**
EBITDA growth (%)	*(14.9%)*	*22.9%*	*61.1%*	*(8.0%)*	*(2.2%)*	*(14.7%)*	*55.7%*	*21.5%*	*24.7%*	*15.2%*	*3.7%*
EBITDA margin (%)	*14.1%*	*12.3%*	*18.8%*	*22.3%*	*19.1%*	*13.2%*	*17.7%*	*18.5%*	*17.4%*	*17.2%*	*17.5%*
Net income, operations	$5,718	$6,169	$10,906	$3,782	$8,692	$3,906	$17,607	$18,708	$15,516	$19,398	$28,226
Net income, adjusted	$5,754	$6,105	$10,898	$9,293	$8,692	$3,945	$17,607	$18,967	$15,516	$19,398	$28,226
EPS, operations	$0.61	$0.59	$1.04	$0.36	$0.81	$0.36	$1.64	$1.77	$1.25	$1.49	$2.17
EPS, adjusted	**$0.61**	**$0.58**	**$1.04**	**$0.88**	**$0.81**	**$0.37**	**$1.64**	**$1.79**	**$1.25**	**$1.49**	**$2.17**
Distribution	$11,310	$12,610	$12,612	$12,702	$12,851	$12,878	$12,872	$12,692	$14,865	$15,589	$15,589
Distribution per share	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20	$1.20
Distributable cash	$17,633	$15,202	$39,974	$41,742	$30,781	$23,136	$37,444	$47,768	$51,697	$69,395	$72,503
Oper cash flow (ex W/C)	$22,702	$28,934	$42,050	$39,924	$37,585	$31,751	$47,118	$54,356	$65,497	$75,693	$78,951
AFFO/free cash flow	$20,047	$24,765	$29,607	$31,249	$27,475	$19,572	$32,370	$39,611	$43,593	$51,683	$52,529
Cash flow per share	$1.99	$1.67	$4.18	$4.01	$2.98	$2.43	$3.82	$4.72	$4.59	$5.78	$6.03
AFFO (FCF) per share	**$2.13**	**$2.36**	**$2.82**	**$2.95**	**$2.57**	**$1.82**	**$3.02**	**$3.75**	**$3.52**	**$3.98**	**$4.04**
Payout ratio (%)	*64.1%*	*83.0%*	*31.6%*	*30.4%*	*41.7%*	*55.7%*	*34.4%*	*26.6%*	*28.8%*	*22.5%*	*21.5%*
FCF yield (%)	*6.1%*	*6.8%*	*8.1%*	*8.5%*	*7.4%*	*5.2%*	*8.6%*	*10.7%*	*10.1%*	*11.4%*	*11.6%*
P/E	*57.2x*	*60.1x*	*33.7x*	*39.8x*	*43.0x*	*94.9x*	*21.3x*	*19.5x*	*27.9x*	*23.4x*	*16.1x*
EV/EBITDA	*24.4x*	*19.8x*	*12.3x*	*13.4x*	*13.7x*	*16.0x*	*10.3x*	*8.5x*	*6.8x*	*5.9x*	*5.7x*

Source: K-Bro Linen financial filings; Leede Financial

- During our coverage history of the firm, we have toured two of K-Bro's flagship laundry processing facilities (its Edmonton- & Mississauga-based facilities, both shortly after they were originally constructed) & continue to be impressed by the levels of automation introduced into baseline operations & thus by the ability of K-Bro to accommodate high processing volumes that allows it to take on substantial long-term contracts, including in

healthcare in SK with 3S Health, in AB with Alberta Health Services & in BC with the Fraser Health Authority & Vancouver Coastal Health Authority as announced in prior years.

- Our original fascination with K-Bro when we initiated our coverage of the firm in late F2013 was based on our interest in just how a laundry processing firm could achieve quarterly EBITDA margin at/above 20%, as K-Bro frequently has during its public company history, while doing so with acquisitive growth that has not compromised its margin profile to any material degree.

- Indeed, during our coverage history, K-Bro has dramatically augmented scale of operations from revenue/EBITDA/margin in FQ313 (the quarter before we initiated coverage on the stock) of $34.6M/$5.7M/16.6% to $155.9M/$32.0M/20.5%; the firm required new equity/debt capital to fund much of the acquisitive growth embedded in that twelve-year growth history (FQ325 debt was $238.8M & was $17.0M back in FQ313; basic S/O in FQ313 was 7.0M & currently is 13.0M) but debt-based financial ratios in the preceding quarter were still well within safe territory in our view at a debt-to-EBITDA run-rate ratio of 1.9x & EBITDA-to-interest coverage ratio of 6.4x.

Exhibit 8. Valuation Scenarios for K-Bro Linen

EPS multiple, F2027	5x	10x	15x	20x	25x	30x	35x
Implied unit price [1,2]	$10.86	$21.73	$32.59	$43.46	$54.32	$65.18	$76.05
AFFO multiple, F2027	**2.5x**	**5x**	**7.5x**	**10x**	**12.5x**	**15x**	**17.5x**
Implied unit price [1,2]	$10.11	$20.22	$30.33	$40.44	$50.55	$60.65	$70.76
EV/EBITDA multiple, F2027	**3x**	**5x**	**7x**	**9x**	**11x**	**13x**	**15x**
Implied share price ($) [1,2]	$7.37	$23.20	$39.04	$54.87	$70.70	$86.53	$102.37
One-year K-Bro Linen target price (C$)				**$46.25**			

[1] *Based on F2027 forecasts (Adjusted EPS $2.17, EBITDA $102.8M, AFFO $4.04/shr)*

[2] *EV incorporates FQ325 cash of $26.0M, total debt of $238.8M, basic S/O of 13.0M*

Source: K-Bro Linen financial filings; Leede Financial

- A core component of our KBL investment thesis is dividend stability, for which payout ratio on FQ325 AFFO of $19.6M was 19.9%. We see no reason that would compel K-Bro to revise its dividend at any time during our F2026/27 forecast period & indeed, the firm has abundant financial flexibility to upwardly revise its annual dividend pay-out of $1.20/shr should its Board choose to endorse such a move.

- KBL share price appreciation has clearly been somewhere between minimal to non-existent in recent years & the pandemic era clearly did not help K-Bro's profitability during the corresponding periods, with notable compression in the firm's hospitality-based linen/laundry processing activities during F2020/21 from which the firm has solidly recovered through a combination of improvements in industry macroenvironment & acquisitive growth in the UK.

- KBL experienced T12M return on share price appreciation alone of (6.9%), though offset somewhat by its 3.4% annual dividend yield, & T24M return of 5.2% (12.0% when considering dividend yield), the latter return making our sustained Buy rating more justifiable in our view. Our current PT of C$46.00 corresponds to a one-year return, including dividend yield, of 35.2%, a magnitude of return that we believe is achievable if the firm can sustain EBITDA margin at/above the 17.0%-to-17.5% annual average in F2026/27 that our model projects. As always, we project seasonal strength during hospitality-intensive FQ2-FQ3 financial periods even while the recent acquisition of UK-based Star Mayan should smooth out seasonal effects on EBITDA/margin originally introduced by the Fishers Topco acquisition back in Nov/17.

- Our $46.00 PT is based on our F2027 adjusted EPS-AFFO-EBITDA forecasts of $2.17/shr-$4.04/shr-$102.8M as shown in Exhibits 7 & 8, with our EV calculation incorporating FQ325 balance sheet data (cash of $26.0M & total

debt of $238.8M as indicated above) & basic S/O of 13.0M, all of which incorporate capital structure revisions introduced by the UK Star Mayan acquisition during FQ225.

- **Cipher Pharmaceuticals (CPH-T, Buy, PT C$19.00).** Cipher's share price strength over the medium term is substantial and rivals Extendicare in our coverage universe on T24M return, which for CPH is 136.6%. In the near term, returns have been admittedly flat (0.3% over T12M & 0.2% over the trailing one-month period, both returns virtually defining the term flat in this context) but we stand by our Buy rating & C$19.00 PT for CPH, with our investment thesis assuming that substantial upside is still on the horizon for Natroba/spinosas in the global head lice/scabies market.

Exhibit 9. Income Statement & Financial Forecast Data for Cipher Pharmaceuticals

Fiscal year-end Dec 31 (US$000, except EPS)	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E	2026E	2027E	2028E
US/RoW, royalty revenue											
Royalty rev, ConZip (US)	552	600	500	430	152	138	33	82	188	188	188
Royalty rev, Lipofen (US)	2,378	2,312	2,400	2,331	2,850	2,175	2,045	1,650	1,813	1,887	1,963
Royalty rev, Absorica (US)	12,942	11,300	9,929	7,648	5,143	6,148	4,545	2,277	2,185	2,185	2,185
Royalty rev, Natroba (RoW)	0	0	0	0	0	0	0	0	1,065	1,666	1,833
Canada/US, direct Rx											
Revenue, Epuris (Cda)	5,813	7,300	8,100	10,885	11,330	10,848	12,980	14,940	15,803	15,921	16,039
Revenue, Vaniqa/Actikerall/ Beteflam/other (Cda)	1,064	939	678	650	1,200	1,753	1,780	2,141	2,457	2,660	2,879
Revenue, Natroba (US)	0	0	0	0	0	0	11,980	30,298	33,328	36,661	40,327
Revenue, Natroba (Cda)	0	0	0	0	0	0	0	0	1,475	1,833	2,016
Total revenue	**$22,749**	**$22,451**	**$21,607**	**$21,944**	**$20,675**	**$21,162**	**$33,363**	**$51,389**	**$58,314**	**$63,001**	**$67,431**
Revenue growth (%)	*(43.6%)*	*(1.3%)*	*(3.8%)*	*1.6%*	*(5.8%)*	*2.4%*	*57.7%*	*54.0%*	*13.5%*	*8.0%*	*7.0%*
Operational expenses	15,984	9,822	8,116	9,294	8,233	8,712	18,237	26,066	30,090	32,578	35,075
EBITDA	**$6,765**	**$12,629**	**$13,491**	**$12,650**	**$12,442**	**$12,450**	**$15,126**	**$25,323**	**$28,224**	**$30,423**	**$32,356**
EBITDA growth (%)	*(74.5%)*	*86.7%*	*6.8%*	*(6.2%)*	*(1.6%)*	*0.1%*	*21.5%*	*67.4%*	*11.5%*	*7.8%*	*6.4%*
EBITDA margin (%)	*29.7%*	*56.3%*	*62.4%*	*57.6%*	*60.2%*	*58.8%*	*45.3%*	*49.3%*	*48.4%*	*48.3%*	*48.0%*
Non-operating expenses	$3,379	$4,570	$6,598	$1,593	$1,392	$2,417	$9,992	$6,950	$8,800	$8,800	$8,800
Net interest exp (income)	$712	$786	$291	$80	($464)	($1,870)	($330)	$1,284	$910	$910	$910
Tax expense, exc tax loss carry-forward	$1,922	$3,071	$3,554	$3,413	($847)	($4,965)	$54	$986	$4,628	$5,178	$5,662
Net income, fully-taxed	**$1,201**	**$2,639**	**$4,386**	**$7,759**	**$26,636**	**$20,383**	**$11,546**	**$17,963**	**$18,514**	**$20,713**	**$22,646**
Fully-taxed EPS (basic)	$0.04	$0.10	$0.16	$0.29	$1.06	$0.81	$0.45	$0.71	$0.73	$0.82	$0.89
Fully-taxed EPS (fd)	**$0.04**	**$0.10**	**$0.16**	**$0.28**	**$1.01**	**$0.78**	**$0.43**	**$0.68**	**$0.70**	**$0.79**	**$0.86**
P/E (basic)	*236.9x*	*108.4x*	*65.5x*	*36.3x*	*10.1x*	*13.2x*	*23.4x*	*15.1x*	*14.6x*	*13.0x*	*11.9x*
EV/EBITDA	*40.9x*	*21.9x*	*20.5x*	*21.9x*	*22.2x*	*22.2x*	*18.3x*	*10.9x*	*9.8x*	*9.1x*	*8.6x*

Source: Cipher Pharmaceuticals financial filings; Leede Financial

- In the US where the drug is already FDA-approved & generating quarterly sales that are meeting our early expectations (FQ325 Natroba sales were US$8.1M, while growing sequentially in each quarter since Cipher assumed US marketing responsibility in FQ324, when US sales were US$5.5M). From that baseline, we believe that Cipher can grow US market share through favorable comparison to Glaxo's (GSK-LN, NR) sodium channel-inhibiting branded permethrin formulation Nix, for which resistant strains are emerging. On the horizon, we expect Cipher to submit a NDS to Health Canada to initiate regulatory review in domestic Rx markets for the drug & we are separately optimistic that the firm can consummate royalty-bearing alliances in RoW markets.

- We endorse the firm's caution on RoW relationships just because of the importance of establishing threshold economics for the first such alliance that the firm puts into the public domain. But once one alliance is announced, we are optimistic that multiple comparable alliances can follow. Though our model does not overtly ascribe value to any future Rx acquisitions, we are optimistic that Cipher can generate sufficient operating cash flow during our forecast period to fund such transactions without substantially revising its capital structure, as was necessary to acquire IN-based Natroba developer ParaPro in Jul/24. We remind Cipher followers that CPH is the best-performing

stock during our healthcare coverage history under the Leede banner, with the stock generating cumulative return since we re-initiated coverage in Jan/21 of 1,145%.

Exhibit 10. Valuation Scenarios for Cipher Pharmaceuticals

Price/earnings multiple, F2027	5x	10x	15x	20x	25x	30x	35x
Implied share price [1]	$3.93	$7.86	$11.80	**$15.73**	$19.66	$23.59	$27.52
EV/EBITDA multiple, F2027	**5x**	**7x**	**9x**	**10x**	**11x**	**13x**	**15x**
Implied share price [1,2]	$5.82	$8.21	$10.61	**$11.81**	$13.01	$15.41	$17.81
One-year Cipher target price (US$)				**$13.77**			
One-year Cipher target price (C$) [3]				**$19.02**			

[1] *Based on F2027 adj EBITDA forecast of US$30.4M, F2027 adj fd EPS of US$0.79, basic S/O 25.4M; fd S/O 26.4M*

[2] *Based on 20x EPS, 10x EV/EBITDA (F2027); FQ325 cash of US$8.4M/C$11.9M, LT debt of US$13.0M/C$18.4M*

[3] *PT in C$ assumes USD:CAD exchange rate of 1.38x*

Source: Cipher Pharmaceuticals financial filings; Leede Financial

- **Medexus Pharmaceuticals (MDP-T, Buy, PT C$8.00).** The main market value driver for ON-based specialty pharmaceutical firm Medexus is US sales traction for its newly-FDA-approved bone marrow conditioning alkylating agent Treosulfan/Grafapex, for which early quarterly sales traction has been encouraging & in fact above our original forecasts for the drug. Medexus itself projects that the drug could achieve an annual sales run-rate of US$100M within five years post-launch, & we agree with that estimate for peak annual sales, though we have a more positive view on the duration required to achieve that sales threshold.

Exhibit 11. Income Statement & Financial Forecast Data for Medexus Pharmaceuticals

Year-end March 31 (US$000, except EPS)	*F2024A*	*F2025A*	*F2026E*	*F2027E*	*F2028E*	*F2029E*	*F2030E*	*F2031E*	*F2032E*	*F2033E*
Product rev, US (exc Treo)	77,182	68,013	56,773	56,739	56,704	56,670	56,636	56,601	56,567	56,533
Treosulfan, US	0	601	15,499	34,814	56,671	81,152	109,217	117,589	126,604	136,309
Product rev, Canada	35,872	39,718	29,530	31,007	32,557	34,185	35,894	37,689	39,573	41,552
Total revenue	**$113,054**	**$108,332**	**$101,802**	**$122,559**	**$145,933**	**$172,007**	**$201,747**	**$211,880**	**$222,744**	**$234,394**
Revenue growth (%)	*4.6%*	*(4.2%)*	*(6.0%)*	*20.4%*	*19.1%*	*17.9%*	*17.3%*	*5.0%*	*5.1%*	*5.2%*
Direct costs	47,985	44,823	37,822	44,968	52,536	60,203	68,594	69,920	71,278	72,662
Gross margin	**65,069**	**63,509**	**63,980**	**77,592**	**93,397**	**111,805**	**133,153**	**141,959**	**151,466**	**161,732**
Gross margin (%)	*57.6%*	*58.6%*	*62.8%*	*63.3%*	*64.0%*	*65.0%*	*66.0%*	*67.0%*	*68.0%*	*69.0%*
SG&A/R&D/other expense	46,007	43,999	48,891	51,029	59,917	69,656	80,586	83,544	86,684	90,014
EBITDA	**$19,062**	**$19,510**	**$15,089**	**$26,562**	**$33,480**	**$42,149**	**$52,566**	**$58,415**	**$64,782**	**$71,718**
EBITDA growth (%)	*20.8%*	*2.4%*	*(22.7%)*	*76.0%*	*26.0%*	*25.9%*	*24.7%*	*11.1%*	*10.9%*	*10.7%*
EBITDA margin (%)	*16.9%*	*18.0%*	*14.8%*	*21.7%*	*22.9%*	*24.5%*	*26.1%*	*27.6%*	*29.1%*	*30.6%*
Non-operating expenses	$8,268	$11,287	$10,796	$7,478	$7,077	$7,828	$8,614	$8,576	$8,521	$8,449
Interest expense (income)	$13,364	$8,195	$5,507	$4,905	$3,764	$3,235	$2,706	$2,176	$1,647	$1,117
Other non-oper expenses	($2,691)	($1,412)	($1,768)	($2,000)	($2,000)	($2,000)	($2,000)	($2,000)	($2,000)	($2,000)
Tax expense (recovery)	$320	($807)	$180	$4,045	$2,509	$1,406	$303	($800)	($1,903)	($3,006)
Net income, fully-taxed	**($199)**	**$2,247**	**$374**	**$12,134**	**$22,129**	**$31,679**	**$42,943**	**$50,463**	**$58,517**	**$67,158**
Fully-taxed EPS (basic)	($0.01)	$0.08	$0.01	$0.37	$0.68	$0.98	$1.32	$1.56	$1.80	$2.07
Fully-taxed EPS (fd)	**($0.01)**	**$0.08**	**$0.01**	**$0.33**	**$0.61**	**$0.87**	**$1.18**	**$1.39**	**$1.61**	**$1.85**
P/E (basic)	*NA*	*25.4x*	*186.6x*	*5.8x*	*3.2x*	*2.2x*	*1.6x*	*1.4x*	*1.2x*	*1.0x*
EV/EBITDA	*4.2x*	*4.1x*	*5.2x*	*3.0x*	*2.4x*	*1.9x*	*1.5x*	*1.4x*	*1.2x*	*1.1x*

Source: Medexus Pharmaceuticals financial filings; Leede Financial

- We agree on the magnitude of the US sales opportunity for this drug, for which unambiguously superior patient outcome data as compared to alternative alkylating agent busulfan were published a few years ago in the journal *Lancet Haematology* from the 476-patient MC-FludT.14/L trial. On its FQ226 conference call in Nov/25, the firm guided capital markets to expect FGQ326 sales for the Dec/25-end period of US$3.5M-to-US$4.0M, a solid level in our view when

considering that early Treosulfan sales could be erratic while wholesale drug distributors balance their own inventories with hospital demand & when considering that we are only three quarters into the drug's US launch history.

- As shown in Exhibit 11, our model projects F2026 Treosulfan/Grafapex US sales of US$15.5M, a level that the drug is well on the way to exceeding based on a FQ326 run-rate basis, US$34.8M in F2027 & US$56.7M in F2028. Medexus' US pharmaceutical sales are experiencing a bit of downdraft from the elimination of the brain imaging drug Gleolan/5-aminolevulinic acid (it was returned to innovator NX development earlier in F2026), but our model expects Treosulfan/Grafapex to substantially offset & exceed historic Gleolan sales performance.

Exhibit 12. Valuation Scenarios for Medexus Pharmaceuticals

Price/earnings multiple, F2027	5x	10x	15x	20x	25x	30x
Implied share price [1]	$1.67	$3.34	**$5.01**	$6.67	$8.34	$10.01
EV/EBITDA multiple, F2027	**5x**	**7.0x**	**8x**	**9.0x**	**11x**	**13x**
Implied share price [1]	$3.99	$5.46	**$6.19**	$6.93	$8.39	$9.86
One-year MDP target price (US$) [1]			**$5.60**			
One-year MDP target price (C$) [2]			**$7.73**			

[1] *Based on adjusted F2027 EBITDA of US$26.6M, F2027 EPS of US$0.33; EV incorporates FQ226 LT debt of US$21.1M, pro forma cash of US$9.4M & S/O of 36.2M*

[2] *PT converted to USD using current exchange rate of 1.38x*

Source: Medexus Pharmaceuticals financial filings; Leede Financial

- We believe that capital markets are transiently cautious on Medexus' cash augmentation capabilities in the medium term, at least while it has pending cash obligations to Treosulfan innovation partner medac GmbH (private), but those payments are expected to conclude during FQ326 (a US$7.5M payment was due at end of the quarter & presumably has been paid; the firm exited FQ226 with US$9.4M in cash, sufficient to fund the payment even before considering any supplemental operating cash flow generated during FQ326), thus allowing the firm's cash reserves to grow in lockstep with Treosulfan-driven operating cash flow growth in coming quarters.

- Going forward, we expect Medexus' operating cash flow to climb sequentially & thus allow the firm to consummate other Treosulfan-like commercialization alliances, probably with a focus on leveraging new US oncology relationships that the firm is building with Treosulfan & thus with an eye on any attractively-valued therapies in the oncology or transplantation markets in which Treosulfan is sold.

- As before, we are maintaining our Buy rating & one-year PT of C$8.00 on MDP, with our valuation based on multiples of our F2027 EBITDA/EPS forecasts (US$26.6M & US$0.33/shr, respectively), as shown in Exhibit 12. Our EV calculation is based on FQ226 balance sheet data (cash of US$9.4M, total debt of US$21.1M) & fd S/O of 36.2M. We remind investors that while MDP shares are up if modestly from the date of our initiation in Sept/24 (13.2% as of this writing), the original impetus behind our initiation was to opine favorably on our view that Treosulfan approval was imminently justified based on all of the clinical data we reviewed & this view turned out to be correct, generating total return to the data of FDA approval announcement of 79.2%. We believe that sustained Treosulfan revenue growth up to or above our current projections can serve as a supplemental value driver during our forecast period.

- **Eupraxia Pharmaceuticals (EPRX-Q, Buy, PT US$11.00).** Earlier this week, BC-based endocrinology-focused small-molecule formulation developer Eupraxia reported highly positive histological response data in the highest dosing cohort in its ongoing Phase II eosinophilic esophagitis (EoE) trial (the Phase Ib/IIa RESOLVE trial) for its DiffuSphere-based fluticacone propionate formulation EP-104GI.

  - Specifically at three-month follow-up, Eupraxia showed in its so-called Cohort 9 that patients treated with 8mg/site across 20 sites (n=3) demonstrated EoEHSS Grade improvement of -0.57 (94% reduction from baseline) and Stage improvement of -0.63 (97% reduction), representing the strongest tissue health improvements observed to date in the trial. These results remain consistent with previously observed dose-dependent efficacy patterns (accounting

for 6mg cohort attenuated response due to catheter delivery issues [actual delivery 1.5-2mg vs. intended 6mg]), with plasma fluticasone propionate levels maintained at approximately 20 pg/mL after an initial transient peak, indicating sustained local delivery without systemic accumulation.

Exhibit 13. Income Statement & Financial Forecast Data for Eupraxia Pharmaceuticals

Year-end December 31 (US$000, exc share data)	*2027E*	*2028E*	*2029E*	*2030E*	*2031E*	*2032E*	*2033E*	*2034E*	*2035E*	*2036E*	*2037E*	*2038E*
EP104GI (EoE), US	$0	$0	$39,677	$79,830	$120,463	$161,581	$203,188	$245,289	$287,887	$330,988	$374,596	$418,715
EP-104GI (EoE), EU	$0	$0	$0	$9,595	$29,072	$58,725	$88,968	$99,842	$110,925	$122,219	$123,441	$135,065
EP104IAR (OA), US	$0	$0	$0	$8,410	$16,921	$34,045	$51,374	$60,296	$69,323	$78,456	$87,696	$105,867
Total revenue	**$0**	**$0**	**$39,677**	**$97,834**	**$166,456**	**$254,351**	**$343,530**	**$405,427**	**$468,135**	**$531,663**	**$585,733**	**$659,647**
Revenue growth (%)	*NA*	*NA*	*NA*	*147%*	*70%*	*53%*	*35%*	*18%*	*15%*	*14%*	*10%*	*13%*
R&D, clinical expenses	$15,958	$12,766	$7,660	$6,128	$5,515	$4,964	$4,467	$4,244	$4,032	$3,830	$3,639	$0
G&A, marketing expenses	$7,698	$8,083	$8,487	$8,911	$9,357	$9,544	$9,735	$9,929	$10,128	$10,331	$10,537	$10,748
Other expenses	$0	$0	$0	$9,919	$4,892	$6,658	$6,359	$6,184	$6,081	$5,618	$5,848	$5,857
EBITDA	**($27,645)**	**($24,041)**	**$6,917**	**$72,460**	**$137,655**	**$222,760**	**$308,908**	**$368,732**	**$429,420**	**$490,186**	**$542,079**	**$612,938**
EBITDA growth (%)	*NA*	*NA*	*NA*	*NA*	*90%*	*62%*	*39%*	*19%*	*16%*	*14%*	*11%*	*13%*
EBITDA margin (%)	*NA*	*NA*	*17%*	*74%*	*83%*	*88%*	*90%*	*91%*	*92%*	*92%*	*93%*	*93%*
Non-operating expenses	$1,795	$1,883	$11,975	$12,071	$7,172	$2,278	$2,390	$2,506	$2,629	$2,757	$2,892	$3,033
EBIT	**($29,441)**	**($25,924)**	**($5,057)**	**$60,389**	**$130,483**	**$220,481**	**$306,518**	**$366,225**	**$426,791**	**$487,429**	**$539,188**	**$609,905**
Other non-oper expenses	($1,313)	($1,378)	($1,447)	($1,519)	($1,595)	($1,675)	($1,759)	($1,847)	($1,939)	($2,036)	($2,138)	($2,245)
EBT	**($28,128)**	**($24,545)**	**($3,610)**	**$61,908**	**$132,078**	**$222,156**	**$308,277**	**$368,072**	**$428,730**	**$489,465**	**$541,325**	**$612,150**
Tax expense	$0	$0	$0	$15,477	$33,020	$55,539	$77,069	$92,018	$107,183	$122,366	$135,331	$153,037
Net income, fully-taxed	($28,128)	($24,545)	($3,610)	$46,431	$99,059	$166,617	$231,208	$276,054	$321,548	$367,099	$405,994	$459,112
Fully-taxed EPS (basic)	($0.53)	($0.47)	($0.07)	$0.85	$1.81	$3.05	$4.23	$5.05	$5.88	$6.72	$7.43	$8.40
Fully-taxed EPS (fd)	**($0.37)**	**($0.32)**	**($0.05)**	**$0.60**	**$1.27**	**$2.14**	**$2.97**	**$3.54**	**$4.13**	**$4.71**	**$5.21**	**$5.89**
P/E (basic)	*NA*	*NA*	*NA*	*12.1x*	*5.7x*	*3.4x*	*2.4x*	*2.0x*	*1.7x*	*1.5x*	*1.4x*	*1.2x*
EV/EBITDA	*NA*	*NA*	*39.9x*	*3.8x*	*2.0x*	*1.2x*	*0.9x*	*0.7x*	*0.6x*	*0.6x*	*0.5x*	*0.5x*
S/O, basic (M)	*52,648*	*52,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*	*54,648*
S/O, fd (M)	*75,935*	*75,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*	*77,935*

Source: Eupraxia Pharmaceuticals financial filings; Leede Financial

- As described in our Oct/25 initiation report, the Eosinophilic Esophagitis Histology Scoring System (EoEHSS) provides a more comprehensive evaluation of disease histopathology over traditional peak eosinophil count (PEC) endpoints. Independent validation published by Ma et al. (Clinical Gastroenterology and Hepatology, 2022) demonstrated EoEHSS exhibits superior responsiveness with standardized effect sizes of 2.18 for grade and 2.07 for stage, compared to more limited capture of histologic changes with PEC alone. The EoEHSS system evaluates eight distinct histopathologic features including eosinophil density, basal zone hyperplasia, eosinophil abscesses, lamina propria fibrosis, and surface epithelial alteration, thereby capturing mucosal remodeling and subepithelial fibrosis that PEC measurement misses entirely. This tissue remodeling and fibrosis contribute to the dysphagia and food impaction characteristic of EoE.

- The -0.57 to -0.63 EoEHSS improvements in Cohort 9 compare favorably to approved therapies, though direct comparisons require caution given the small sample size, open-label design, and differing assessment timepoints. Dupixent achieved EoEHSS improvements in the -0.25 to -0.30 range at 24 weeks in Phase 3 trials. The upcoming Phase 2b data (Topline Q3 2026, 120-patient randomized controlled cohort) remains important in determining next steps, though we maintain expectations for late 2026 FDA interaction and H1 2027 Phase 3 initiation.

- We remain highly positive about EP-104GI's medical prospects in EoE based on RESOLVE data already reported, as well as equally positive about the partnerability of the same drug under a different name (EP-104IAR) in knee osteoarthritis pain, for which Phase II data were positive & published last year. We are separately positive about Eupraxia's ability to make DiffuSphere available to other drug development partners seeking to achieve sustained localized delivery of other agents in other indications, with royalty-based economics flowing back to Eupraxia without any material supplemental R&D expense obligations for the firm. We are maintaining our Buy rating & PT of US$11.00 on EPRX, with our valuation based on NPV (25%) & multiples of our F2031 EBITDA/EPS forecasts of US$137.7M & US$1.27/shr respectively, as shown in Exhibit 14. The stock is performing well since our Oct/25 initiation & is up 58% since then.

Exhibit 14. Valuation Scenarios for Eupraxia Pharmaceuticals

NPV, discount rate		15%	20%	25%	30%	35%	45%
Implied value per share		$28.67	$18.47	**$12.16**	$8.15	$5.53	$2.56
Price/earnings multiple, 2031E		**15%**	**20%**	**25%**	**30%**	**35%**	**45%**
Implied share price[1,2]	**10**	$7.27	$6.13	$5.21	$4.45	$3.83	$2.88
	20	$14.53	$12.26	**$10.41**	$8.90	$7.65	$9.24
	30	$21.80	$18.39	$15.62	$13.35	$11.48	$13.86
EV/EBITDA multiple, 2031E		**7.5x**	**10x**	**12.5x**	**15x**	**17.5x**	**20x**
Implied share price[1,2]		$5.89	$7.70	**$9.51**	$11.32	$13.13	$14.94
One-year EPRX target price (US$)[1,2]				**$10.69**			

[1] *Based on F2031 fd fully-taxed EPS of $1.27; EBITDA of $137.7M, discounted at 25%, current basic S/O 50.6M*

[2] *Enterprise value based on fd S/O of 73.9M; FQ325 cash of US$89.0M, no LT debt*

Source: Eupraxia Pharmaceuticals financial filings; Leede Financial

- **Profound Medical (PROF-Q, Buy, PT US$15.50).** The rubber is expected to hit the road this year for our investment thesis on ON-based ultrasound ablation technology developer Profound Medical, with no impediments remaining that can get in the way of US adoption for its MR-guided prostate gland-targeted ultrasound ablation platform TULSA-PRO – device-specific US reimbursement codes have been in place since Jan/25 (removing any complications to TULSA-PRO adoption for either capital equipment- or procedure-based reasons), the device has performed well in virtually every clinical study we have reviewed (excluding any variability in patient outcomes that is usually caused by physician inexperience & not device inadequacies) showing substantial prostate disease mitigation with the focused ultrasound energy that TULSA-PRO applies, & Profound has a US commercial team in place to drive adoption by US healthcare facilities equipped with MR imaging functionality, a list of which includes most US hospitals as well as multiple urology or imaging centers nationwide.

Exhibit 15. Income Statement & Financial Forecast Data for Profound Medical

Year-end December 31 (US$000, exc per share data)	2023A	2024A	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
TULSA-PRO, capital equipment	393	7,300	10,620	26,813	52,008	93,830	148,467	222,772	290,532	367,092
TULSA-PRO, accessories	5,607	940	1,179	1,268	1,866	2,596	3,466	3,941	4,416	4,891
Service, maintenance	0	2,440	5,193	18,500	24,000	30,000	36,000	36,000	36,000	36,000
Total prod revenue	**6,000**	**10,680**	**16,992**	**46,581**	**77,874**	**126,426**	**187,933**	**262,713**	**330,948**	**407,983**
Revenue growth, y/y (%)	*0%*	*78%*	*59%*	*174%*	*67%*	*62%*	*49%*	*40%*	*26%*	*23%*
Gross margin	**4,382**	**7,037**	**12,006**	**30,907**	**53,205**	**88,361**	**131,553**	**183,899**	**231,664**	**285,588**
Gross margin (%)	*73.0%*	*65.9%*	*70.7%*	*66.4%*	*68.3%*	*69.9%*	*70.0%*	*70.0%*	*70.0%*	*70.0%*
Cumulative operating expenses	28,435	36,582	51,501	66,948	54,410	49,435	62,018	74,873	89,356	106,076
EBITDA	**(24,053)**	**(29,545)**	**(39,495)**	**(36,041)**	**(1,205)**	**38,927**	**69,535**	**109,026**	**142,308**	**179,513**
EBITDA margin (%)	*NA*	*NA*	*NA*	*NA*	*NA*	*31%*	*37%*	*42%*	*43%*	*44%*
EBITDA growth, y/y (%)	*NA*	*NA*	*NA*	*NA*	*NA*	*(3,331%)*	*79%*	*57%*	*31%*	*26%*
Cumulative non-oper expenses (amort, stock option, interest)	8,822	(1,727)	5,338	1,972	1,972	1,972	1,972	1,972	1,972	1,972
Tax expense	0	(2)	226	0	1,072	9,239	16,891	26,764	35,084	44,385
Net Income, fully-taxed	**(8,822)**	**(27,816)**	**(45,059)**	**(38,013)**	**(4,248)**	**27,716**	**50,673**	**80,291**	**105,252**	**133,155**
EPS (basic)	($0.40)	($1.13)	($1.40)	($1.00)	($0.11)	$0.73	$1.34	$2.12	$2.78	$3.52
EPS (fd)	**($0.37)**	**($1.07)**	**($1.33)**	**($0.97)**	**($0.11)**	**$0.71**	**$1.29**	**$2.04**	**$2.68**	**$3.39**
P/E	*NA*	*NA*	*NA*	*NA*	*NA*	*11.0x*	*6.0x*	*3.8x*	*2.9x*	*2.3x*
EV/EBITDA (basic S/O)	*NA*	*NA*	*NA*	*NA*	*NA*	*0.8x*	*0.5x*	*0.3x*	*0.2x*	*0.2x*

Source: Profound Medical financial filings; Leede Financial

- As we described in our Nov 14th Healthcare Weekly, Profound's FQ325 consolidated revenue of US$5.3M was dominated by US$3.8M in procedure-based consumables revenue, a revenue component that we expect to drive top-line growth in combination with TULSA-PRO capital sales & leasing relationships, the latter coming in at a more

modest US$1.2M in the quarter but with our expectations for capital sales to grow substantially this year. The firm now has seventy TULSA-PRO systems installed, mostly in the US, & it has ninety-three TULSA-PRO systems in its backlog at various stages of consideration by targeted healthcare facilities. For now, our model will continue to assume that TULSA-PRO can sell in US markets for about US$0.5M per system, with consumables (endorectal cooling probes & ultrasound transducer) priced at US$5,500 per procedure, consistent with company guidance.

- Final data from the ongoing 201-patient CAPTAIN trial, in which patient outcomes for TULSA-PRO ablation are compared to da Vince surgical robot-enabled radical prostatectomy on prostate cancer recurrence rate & safety/morbidity profile, are expected later this year but early interim data are encouraging. There is of course no possibility for TULSA-PRO patients to outperform radical prostatectomy patients on localized disease recurrence (the gland is no longer available to become cancerous again in prostatectomized patients, after all) but on side effect profile, TULSA-PRO is already performing well on magnitude of blood loss (lower), on duration of hospital-based recovery (shorter) & on post-operative pain (less intense), as documented at the 2025 RSNA meeting late last year.

Exhibit 16. Valuation Scenarios for Profound Medical

NPV, discount rate		5%	10%	15%	20%	25%	30%
Implied value per share		$39.18	$27.86	$20.09	**$14.66**	$10.79	$7.98
Price/earnings multiple, F2029	**P/E**	**5%**	**10%**	**15%**	**20%**	**25%**	**30%**
Implied share price[1]	10	$12.22	$11.13	$10.18	$9.35	$8.62	$7.97
	20	$24.44	$22.26	$20.36	**$17.90**	$17.24	$15.94
	30	$36.66	$33.39	$30.54	$28.05	$25.86	$23.91
EV/EBITDA multiple, F2029		**5x**	**7.5x**	**10x**	**12.5x**	**15x**	**17.5x**
Implied share price[1,2]		$6.01	$8.56	$11.12	**$13.68**	$16.24	$18.80
One-year Profound Medical target price (US$) [1,2]				**$15.42**			

[1] *F2029 fully-diluted fully-taxed EPS (basic) forecast $1.29/shr; EBITDA $69.5M; NPV discounted at 20%; fd S/O 39.3M incorporates new equity offering consummated in Dec/25*

[2] *Balance sheet includes pro forma cash of US$64.7M (FQ325 cash of US$24.8M, plus calculated net proceeds from Dec/25 equity offering; FQ325 LT debt of US$4.5M)*

Source: Profound Medical financial filings; Leede Financial

- We take a back seat to no one in our praise of TULSA-PRO's medical prospects as a substitute or supplemental therapy to da Vinci surgical robot/radical prostatectomy or TrueBeam-based radiation therapy in the localized prostate disease continuum, & we believe that TULSA-PRO's clinical history – including in Profound's pivotal 110-patient TACT trial on which positive FDA review was based – can support more aggressive US adoption now that all economic levers are in place to support that adoption. We are maintaining our Buy rating & US$15.50 PT on PRN, with our valuation still based on NPV (20% discount rate) & multiples of our F2029 adjusted EBITDA/EPS forecasts of US$69.5M & US$1.55/shr, respectively.

- Our EV is based on the firm's pro forma cash of US$64.7M that includes FQ325 cash of US$24.8M plus proceeds from the firm's Dec/25 equity offering & LT debt of US$4.5M, along with pro forma fd S/O of 39.3M that also gives effect to the aforementioned equity offering. PRN share value was certainly challenged during much of F2025, during which expectations for pace of TULSA-PRO adoption likely fell below expectations, including our own, but that sentiment has clearly moderated in recent trading sessions with PRN shares up 106% since early Sept/25 (T12M return is modest but still positive at 10.4%).

- **Perimeter Medical Imaging (PINK-V, Spec Buy, PT C$3.00).** Similar to our Profound Medical commentary above, our investment thesis for Perimeter is similarly positive for how F2026 should be a transformative year for the firm. FDA review for the firm's AI-enabled optical coherence tomography (OCT)-based breast tumor margin-assessing B-Series platform should conclude later this year (& in fact, we believe that it could conclude favorably later this quarter) & if approved as we expect it to be, we believe that Perimeter & its existing marketing team can drive system adoption at

an accelerated pace as compared to that currently being achieve for the firm's first-generation FDA-approved S-Series breast tumor imaging platform.

Exhibit 17. Income Statement & Financial Forecast Data for Perimeter Medical Imaging

Year-end December 31 *(US$000, exc per share data)*	2024A	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
OCT, capital equipment, US	0	1,050	3,188	4,148	5,286	6,608	8,439	10,635	11,251	11,881	12,692
OCT, capital equipment, EU	0	0	0	1,470	2,975	3,870	5,005	6,386	6,686	6,540	5,934
OCT, consumables, US	487	672	2,270	5,855	13,825	28,359	60,068	86,719	114,133	144,685	177,261
OCT, consumables, EU	0	0	52	774	3,262	7,720	15,387	23,080	33,000	45,702	61,612
Service/maintenance, US/EU	0	420	1,151	2,351	4,063	6,339	9,376	13,395	17,691	22,152	26,685
Operating leases	359	500	500	500	500	500	500	500	500	500	500
Total revenue	**846**	**2,642**	**7,161**	**15,097**	**29,910**	**53,396**	**98,774**	**140,715**	**183,261**	**231,461**	**284,684**
Revenue growth, y/y (%)	*110%*	*212%*	*171%*	*111%*	*98%*	*79%*	*85%*	*42%*	*30%*	*26%*	*23%*
Gross margin	**754**	**979**	**3,659**	**9,919**	**20,368**	**37,427**	**70,719**	**101,281**	**132,961**	**168,990**	**208,856**
Gross margin, capital equipment	*NA*	*NA*	*25.0%*	*40.0%*	*50.0%*	*50.0%*	*50.0%*	*50.0%*	*50.0%*	*50.0%*	*50.0%*
Gross margin, serv/maint, OCT (%)	*86.6%*	*89.2%*	*45.0%*	*60.0%*	*75.0%*	*75.0%*	*75.0%*	*75.0%*	*75.0%*	*75.0%*	*75.0%*
Operating costs, grant income	16,826	16,410	15,203	17,102	16,938	16,829	16,574	16,874	16,981	17,093	17,628
EBITDA	**(16,072)**	**(15,431)**	**(11,544)**	**(7,183)**	**3,430**	**20,598**	**54,146**	**84,407**	**115,980**	**151,898**	**191,228**
EBITDA margin (%)	*NA*	*NA*	*NA*	*NA*	*11%*	*39%*	*55%*	*60%*	*63%*	*66%*	*67%*
EBITDA growth, y/y (%)	*NA*	*NA*	*NA*	*NA*	*(148%)*	*501%*	*163%*	*56%*	*37%*	*31%*	*26%*
Net Income, fully-taxed	(13,394)	(14,681)	(10,794)	(6,433)	3,135	16,011	41,172	63,868	87,548	114,486	143,984
EPS (basic)	($0.14)	($0.11)	($0.08)	($0.05)	$0.02	$0.12	$0.31	$0.49	$0.67	$0.87	$1.10
EPS (fd)	**($0.11)**	**($0.08)**	**($0.06)**	**($0.04)**	**$0.02**	**$0.09**	**$0.24**	**$0.37**	**$0.50**	**$0.66**	**$0.83**
S/O (basic)	*93,514*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*	*131,121*
S/O (fd)	*118,442*	*193,655*	*173,898*	*173,898*	*173,898*	*173,898*	*173,898*	*173,898*	*173,898*	*173,898*	*173,898*
Units placed or sold, US/EU	*8*	*17*	*46*	*71*	*98*	*128*	*168*	*219*	*229*	*234*	*235*
Cumulative installed base	*11*	*28*	*74*	*145*	*243*	*371*	*539*	*758*	*987*	*1,221*	*1,456*
P/E	*NA*	*NA*	*NA*	*NA*	*19.1x*	*3.7x*	*1.5x*	*0.9x*	*0.7x*	*0.5x*	*0.4x*
EV/EBITDA (basic S/O)	*NA*	*NA*	*NA*	*NA*	*8.9x*	*1.5x*	*0.6x*	*0.4x*	*0.3x*	*0.2x*	*0.2x*

Source: Perimeter Medical Imaging financial filings; Leede Financial

- Earlier this week, Perimeter announced an expanded alliance with UT-based healthcare services manager Intermountain Health (private), ostensibly to leverage Intermountain's existing healthcare network as a target market for S-Series, & presumably for B-Series once approved. Perimeter does not have the scale of marketing infrastructure that can comprehensively target the US oncology imaging market (though oncology services are conveniently concentrated in a handful of oncology-intensive centers in TX-WA-MA-NY-PA & a few other geographies) so we are positive about relationships like this, providing that the partner is as committed to S-Series adoption as Perimeter is. As initial evidence of the alliance's attractiveness, Intermountain already placed two S-Series devices in UT-based hospitals & it is conceivable that the other thirty-two hospitals in Intermountain's network could be similarly receptive to S-Series adoption.

- As before, we are maintaining our Spec Buy rating & one-year PT of $3.00 on PINK, with our valuation based on NPV (25% discount rate) & multiples of our F2030 EBITDA/EPS forecasts. The firm is undercapitalized based on all of the commercial & manufacturing activities that we see on the horizon for Perimeter, so alliance with Intermountain & its peers could be cost-effective initiatives to drive device adoption without excessive revision to the firm's capital structure.

Exhibit 18. Valuation Scenarios for Perimeter Medical Imaging

NPV, discount rate		10%	15%	20%	25%	30%	40%
Implied value per share		$10.35	$6.54	$4.21	**$2.43**	$1.83	$0.81
Price/earnings multiple, F2030	**P/E**	**10%**	**15%**	**20%**	**25%**	**30%**	**40%**
Implied share price[1]	10	$2.06	$1.72	$1.45	$1.23	$1.05	$0.78
	20	$4.12	$3.44	$2.90	**$2.42**	$2.10	$1.56
	30	$6.18	$5.16	$4.35	$3.69	$3.15	$2.34
EV/EBITDA multiple, F2030		**5x**	**7.5x**	**10x**	**12.5x**	**15x**	**17.5x**
Implied share price[1,2]		$0.64	$0.96	$1.28	**$1.60**	$1.92	$2.24
One-year Perimeter Medical target price [1,2]					**$2.15**		
One-year Perimeter Medical target price [1,2,3]					**$2.97**		

[1] *F2030 fully-taxed EPS (fd) forecast US$0.27, EBITDA US$53.9M; NPV discounted at 25%; fd S/O 154.1M*

[2] *Balance sheet data includes FQ325 cash of US$1.7M/C$8.5M, no LT debt; current basic S/O 111.4M*

[3] *Price target converted to USD using exchange rate of 1.38x*

Source: Perimeter Medical Imaging financial filings; Leede Financial

- **Nanalysis Scientific (NSCI-V, Spec Buy, PT C$0.50).** Our investment thesis for AB-based low-field benchtop NMR developer & security services provider Nanalysis is unchanged from our last update in late Nov/25, with the firm experiencing three consecutive quarters of soft EBITDA as fueled by two distinctive business elements – softening sales trajectory for its 60MHz & 100MHz NMR platforms in what its peers (specifically but not exclusively its UK-based peer Oxford Instruments [OXIG-LN, NR]) are also characterizing as a soft global analytical equipment market, plus sustainably soft gross margin from its security services contract with CATSA (Canadian Air Transport Security Authority) originally announced back in F2022.

Exhibit 19. Income Statement & Financial Forecast Data for Nanalysis Scientific

Year-end Dec 31 (C$000, except EPS)	F2018A	F2019A	F2020A	F2021A	F2022A	F2023A	F2024A	F2025E	F2026E	F2027E	F2028E
Revenue, categorized by acquisition history (F2018-to-F2022)											
Nanalysis, Quad Sys, One Moon	*8,381*	*8,364*	*5,731*	*10,590*	*15,042*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*
RS2D SAS	*0*	*0*	*2,143*	*5,453*	*2,655*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*
K'Prime Technol (CATSA)	*0*	*0*	*0*	*0*	*7,124*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*
Revenue, categorized by business segment (F2018A-to-F2028E)											
Scientific instruments	8,381	8,364	7,874	16,043	21,588	16,342	19,396	14,789	16,409	17,229	18,286
Security services	0	0	0	0	3,233	10,481	21,010	23,529	26,625	28,759	30,892
Total revenue	**$8,381**	**$8,364**	**$7,874**	**$16,043**	**$24,821**	**$28,466**	**$45,495**	**$41,259**	**$43,035**	**$45,988**	**$49,178**
Revenue growth (%)	*NA*	*(0.2%)*	*(5.9%)*	*103.7%*	*54.7%*	*14.7%*	*59.8%*	*(9.3%)*	*4.3%*	*6.9%*	*6.9%*
Direct costs	2,983	2,304	2,707	5,803	11,079	9,609	9,188	6,953	7,108	6,579	6,617
Gross margin	5,398	6,060	5,167	10,240	10,469	3,971	12,746	10,394	14,845	19,654	23,254
Gross margin (%)	*64.4%*	*72.5%*	*65.6%*	*63.8%*	*42.2%*	*13.9%*	*28.0%*	*25.2%*	*34.5%*	*42.7%*	*47.3%*
Operating expenses	4,480	5,015	6,811	8,335	15,074	12,045	10,810	10,228	8,789	8,172	8,285
EBITDA	**$918**	**$1,045**	**($1,644)**	**$1,905**	**($4,605)**	**($8,074)**	**$1,936**	**$166**	**$6,057**	**$11,483**	**$14,969**
EBITDA margin (%)	*11.0%*	*12.5%*	*NA*	*11.9%*	*NA*	*NA*	*4.3%*	*0.4%*	*14.1%*	*25.0%*	*30.4%*
EBITDA growth (%)	*NA*	*13.8%*	*NA*	*NA*	*NA*	*NA*	*NA*	*(91.4%)*	*3,555.5%*	*89.6%*	*30.4%*
Loss (income) on Quad Systems	0	0	0	0	0	527	1,085	0	0	0	0
Non-operating expenses	$630	$2,290	$2,365	$3,641	$6,224	$4,494	$5,381	$4,648	$4,799	$4,799	$4,799
EBIT	**$288**	**($1,245)**	**($4,009)**	**($1,736)**	**($10,829)**	**($12,568)**	**($3,445)**	**($4,482)**	**$1,257**	**$6,683**	**$10,169**
Int exp (income), curr exch	$152	$154	($34)	$36	$240	$3,700	$1,779	$1,406	$1,599	$1,543	$1,487
Tax expense	$62	$261	($297)	$0	($484)	($11)	($22)	$35	$282	$1,285	$2,171
Net income, fully-taxed	$74	($1,660)	($3,463)	($1,822)	($9,781)	($16,839)	($13,421)	($5,924)	($624)	$3,855	$6,512
Fully-taxed EPS (basic)	**$0.001**	**($0.024)**	**($0.053)**	**($0.025)**	**($0.104)**	**($0.169)**	**($0.119)**	**($0.052)**	**($0.006)**	**$0.034**	**$0.058**
Fully-taxed EPS (fd)	$0.001	($0.022)	($0.047)	($0.023)	($0.092)	($0.144)	($0.103)	($0.045)	($0.005)	$0.030	$0.050
P/E (basic)	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*4.8x*	*2.9x*
EV/EBITDA	*38.7x*	*34.0x*	*NA*	*18.6x*	*NA*	*NA*	*18.3x*	*214.3x*	*5.9x*	*3.1x*	*2.4x*

Source: Nanalysis Scientific financial filings; Leede Financial

- NMR system sales were notably soft in Europe, as compared to F2024 when sales were strong at least by Nanalysis' own standards. US NMR sales were also trending downward throughout F2025, as compared specifically to F2022 when US sales were strong by trailing standard.
- We are optimistic that the firm's historic seasonal FQ4 strength specifically on NMR equipment sales traction will be realized in FQ425 as well, with our model projecting full-year F2025 revenue/gross margin/EBITDA of $41.3M/$10.4M/$0.2M but with sequential improvement on all metrics to $43.0M/$14.8M/$6.1M in F2026 & to $46.0M/$19.7M/$11.5M in F2027, with the latter year serving as the reference year in our EBITDA/EPS-based valuation methodologies, as shown in Exhibit 20.
- The firm is as of this writing undertaking a stopgap equity offering, presumably to mitigate the need to augment its outstanding debt that is already above cautionary levels & we will watch for consummation of this transaction in coming weeks. We stand by our view that low-field benchtop NMR functionality is still at early days of its adoption cycle in both academic/government & commercial markets & Nanalysis is well-positioned in our view to grow its market share in this niche analytical instrumentation market currently comprised of systems developed by Nanalysis of course but also NZ-based Magritek (private), the aforementioned Oxford Instruments & by instrumentation giant Bruker (BRKR-Q, NR).

Exhibit 20. Valuation Scenarios for Nanalysis Scientific

Price/earnings multiple, F2027	5x	10x	15x	20x	25x	30x
Implied share price [1]	$0.15	$0.30	**$0.44**	$0.59	$0.74	$0.89
EV/EBITDA multiple, F2027	**5x**	**7x**	**8x**	**9x**	**10x**	**12x**
Implied share price [1]	$0.31	$0.49	**$0.58**	$0.67	$0.76	$0.93
One-year NSCI target price (C$) [1]			**$0.51**			

[1] *Based on adjusted F2027 EBITDA of $11.5M, F2027 EPS of $0.030, discounted by 10.0%; EV incorporates FQ225 cash of $0.4M, LT debt of $17.0M, and fd S/O of 130.1M*

Source: Nanalysis Scientific financial filings; Leede Financial

- **Sernova Biotherapeutics (SVA-T, Spec Buy, PT C$1.50).** ON-based medical technology developer Sernova continues to test its implantable cell reservoir device Cell Pouch in regenerative & transplantation markets focused on type I diabetes. The firm is supporting an ongoing Phase I islet transplantation trial at the University of Chicago for which impressive insulin independence data from patients undergoing islet transplantation procedures are already in the public domain, nicely showing that Cell Pouch's ability to support islet function in a well-vascularized, minimally fibrosed subcutaneously-implanted environment should position the device well for supporting function of various cells or tissues that could be deployed within it.
  - In collaboration with the University of Chicago, Sernova is currently enrolling islet transplantation patients into a distinct cohort that will receive a larger Cell Pouch design, in which a larger number of cell reservoir channels are incorporated to allow for more islets to be implanted over a more diffuse geometry than is achievable with a smaller channel number device. In our view, this trial long ago established all of the functionality that we expect of Cell Pouch in the transplantation/regenerative medicine continuum & our own attention is shifting to other initiatives, as described below.
  - These include testing the utility of tegoprubart/AT-1501 as an immunosuppressive agent in Cell Pouch patients. This anti-CD40L mAb was designed by CA-based partner Eledon Pharmaceuticals (ELDN-Q, NR) with which Sernova announced a development alliance back in July/25. AT-1501 performed well in a porcine heart xenotransplantation procedure described in early F2025 in the journal Nature Medicine & notwithstanding capital market response to Eledon's initial human clinical testing reported last year, the drug did not engender any of the nephrotoxicity or blood glucose dysregulation that other immunosuppressive agents (cyclosporine A/Sandimmune or tacrolimus/Prograf, respectively) confer, the mitigation of which is the raison d'etre for developing next-generation

immunosuppressive regimens in the first place. We expect AT-1501 data to emerge from a new nine-patient cohort in the University of Chicago Cell Pouch study later this year.

- Over the medium-term, we are optimistic that Sernova's other seminal alliance partner Evotec (EVT-DE, NR) can resolve all scale-up manufacturing logistics for producing its stem cell-derived islet platform iBeta to clinical scale & thus allow for a Phase I type I diabetes/islet transplantation study incorporating Cell Pouch & iBeta into study protocol, thus substituting iBeta for cadaver-derived islets that are being tested in the University of Chicago study so far. It is not yet clear if Evotec or Sernova's University of Chicago collaborators would be the lead investigators on this trial but we look for details on this theme in coming months.

Exhibit 21. Income Statement & Financial Forecast Data for Sernova Biotherapeutics

Year-end October 31 (C$000, excl. per share data)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
Revenue										
Cell Pouch, T1D	601	1,338	2,983	19,507	51,427	66,320	82,196	77,514	80,004	82,491
Cell Pouch, hemophilia A	0	0	0	1,126	5,798	8,960	12,307	15,214	18,286	21,530
Cell Pouch, hyperthyroidemia	0	0	0	0	0	1,983	5,158	8,586	11,166	13,940
Cell therapy, T1D	0	0	0	37,635	158,925	307,523	485,335	664,291	853,930	1,054,323
Cell therapy, hemophilia A	0	0	0	1,456	8,811	19,954	34,960	53,147	74,577	99,313
Cell therapy, hyperthyroidism	0	0	0	0	0	2,466	8,755	19,018	32,103	48,119
Total revenue	**601**	**1,338**	**2,983**	**59,724**	**224,962**	**407,206**	**628,710**	**837,769**	**1,070,065**	**1,319,716**
Revenue growth (%, y/y)	*NA*	*123%*	*123%*	*1,902%*	*277%*	*81%*	*54%*	*33%*	*28%*	*23%*
Gross margin	**330**	**736**	**1,641**	**38,712**	**148,889**	**273,455**	**425,148**	**571,241**	**732,627**	**906,107**
Gross margin (%)	*NA*	*55%*	*55%*	*65%*	*66%*	*67%*	*68%*	*68%*	*68%*	*69%*
Milestone revenue	(15,000)	(12,500)	(10,000)	(7,500)	(7,500)	(7,500)	(7,500)	(7,500)	(7,500)	(7,500)
R&D expense	20,000	15,000	10,000	8,000	8,000	8,000	8,000	8,000	8,000	8,000
Other operating costs	5,546	5,855	6,197	8,472	13,723	23,211	33,322	41,051	48,153	54,108
EBITDA	**(10,215)**	**(7,619)**	**(4,556)**	**29,740**	**134,667**	**249,744**	**391,326**	**529,691**	**683,975**	**851,499**
EBITDA margin (%)	*NA*	*NA*	*NA*	*49.8%*	*59.9%*	*61.3%*	*62.2%*	*63.2%*	*63.9%*	*64.5%*
EBITDA growth (%, y/y)	*NA*	*NA*	*NA*	*NA*	*352.8%*	*85.5%*	*56.7%*	*35.4%*	*29.1%*	*24.5%*
Non-oper exp (income)	1,456	1,456	1,456	1,456	1,456	1,456	1,456	1,456	1,456	1,456
Interest expense	0	0	0	0	0	0	0	0	0	0
Tax expense	0	0	0	9,935	46,659	86,936	136,490	184,917	238,917	297,550
Less: tax loss carryforwards	0	0	0	(9,935)	(46,659)	(4,990)	0	0	0	0
Net Income (loss)	**(11,571)**	**(8,975)**	**(5,912)**	**28,385**	**133,311**	**166,443**	**253,481**	**343,418**	**443,702**	**552,593**
Net inc (loss) (fully-taxed)	(11,571)	(8,975)	(5,912)	18,450	86,652	161,452	253,481	343,418	443,702	552,593
EPS (basic)	($0.03)	($0.02)	($0.01)	$0.07	$0.34	$0.42	$0.64	$0.87	$1.12	$1.40
EPS (fd, fully-taxed)	**($0.02)**	**($0.02)**	**($0.01)**	**$0.06**	**$0.27**	**$0.34**	**$0.51**	**$0.70**	**$0.90**	**$1.12**
Shares outstanding (basic)	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*	*394,831*
Shares outstanding (fd)	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*	*493,687*
P/E	*NA*	*NA*	*NA*	*2.4x*	*0.5x*	*0.4x*	*0.3x*	*0.2x*	*0.2x*	*0.1x*
EV/EBITDA	*NA*	*NA*	*NA*	*1.9x*	*0.4x*	*0.2x*	*0.1x*	*0.1x*	*0.1x*	*0.1x*

Source: Sernova Biotherapeutics financial filings; Leede Financial

- We would be remiss not to acknowledge that Sernova requires capital to sustain its ongoing Cell Pouch development activities (its FQ325 cash balance was negligible) but we are optimistic that the firm can secure capital from various investor or philanthropic sources in coming months. We stand by our view that Cell Pouch, or next-generation manifestations of same, will in time be seen as indispensable for sustaining biological activity of regenerative therapies deployed within it, & at this point in Sernova's evolution, we have abundant evidence of this from Phase I testing in islet transplantation, in thyroid disease with the firm's University of British Columbia collaboration in thyroid cell transplantation or in hemophilia B with its preclinical testing of Factor VIII-expressing recombinant blood endothelial cells, all of which have generated positive data that is in the public domain in peer-reviewed form. Our SVA valuation as indicated in Exhibit 22 is based on NPV (25% discount rate) & multiples of

our F2030 EBITDA/EPS forecasts, but we will have clear evidence of Cell Pouch's prospects long before that in our view, with F2026 featured as a seminal financial period for the firm's type I diabetes/islet transplantation clinical initiatives.

Exhibit 22. Valuation Scenarios for Sernova Biotherapeutics

NPV, discount rate		15%	20%	25%	30%	40%	50%
Implied value per share		$5.91	$3.84	$2.55	**$1.72**	$0.82	$0.41
Price/earnings multiple, F2030		**15%**	**20%**	**25%**	**30%**	**40%**	**50%**
Implied share price[1]	10	$1.68	$1.35	$1.10	$0.91	$0.63	$0.44
	20	$3.36	$2.70	$2.20	**$1.82**	$1.26	$0.88
	30	$5.04	$4.05	$3.30	$2.73	$1.89	$1.32
EV/EBITDA multiple, F2030		**5x**	**10x**	**12.5x**	**15x**	**17.5x**	**20x**
Implied share price[1,2]		$0.37	$0.73	$0.92	**$1.10**	$1.29	$1.47
One-year Sernova target price [1,2]				**$1.55**			

[1,2] F2030 EPS (fd) forecast $0.27; EBITDA forecast $134.7M; NPV discounted at 30%; pro forma basic S/O 394.8M, pro forma fd S/O 493.7M; FQ325 cash of $0.1M, convertible debt of $0.95M

Source: Sernova Biotherapeutics financial filings; Leede Financial

- **Cardiol Therapeutics (CRDL-T, Spec Buy, PT C$7.00).** ON-based Cardiol is expected by us to remain focused on clinical activities for its flagship orally-active ultra-pure synthetic cannabidiol formulation CardiolRx, for which the firm provided final Phase II data late last year for its 109-patient ARCHER trial, testing CardiolRx as an anti-inflammatory agent in patients with acute myocarditis.
  - As we described in our Dec/25 CRDL report, the trial did not strictly-speaking achieve its primary endpoint on impacting measurable elements of heart structure/physiology like MR-verified change in extracellular volume or global longitudinal strain) but other data in our view were highly supportive of CardiolRx's impact on inflammatory pathways underlying myocarditis disease pathology, including on mitigating left ventricular mass (a hallmark symptom of congestive heart disease is left ventricle hypertrophy) & left atrial end-systolic volume, while other measures of myocarditis-based heart pathology favored CardiolRx if not quite to a statistically-significant degree. We inferred from Cardiol's commentary that acute myocarditis will be transiently de-prioritized in favor of two other cardiovascular indications, led by advanced CardiolRx clinical testing in recurrent pericarditis & by IND-enabling studies for a subcutaneous cannabidiol formulation CRD-38 intended to target diastolic heart failure (also called heart failure with preserved ejection fraction; HFpEF).
  - A separate 110-patient Phase III recurrent pericarditis trial (the MAvERIC trial) is already ongoing, in which Cardiol is testing CardiolRx in patients who discontinued therapy with an FDA-approved alternative interleukin-1-blocking agent rilonacept/Arcalyst began patient enrollment in April/25 & our model assumes that if patient enrollment concludes in the next quarter or two (patients should not be challenging to identify, since rilonacept/Arcalyst has been FDA-approved since Mar/21), we believe that Cardiol could report six-month efficacy data on pericarditis recurrence rate & impact on Numeric Rating Scale pain scores by end-of-FQ426.(CardiolRx performed well in an earlier exploratory open-label Phase II trial, the 27-patient MAvERIC-Pilot trial, as reported back in Nov/24 at the annual American Heart Association meeting).
  - Our model separately assumes that IND-enabling preclinical testing for CRD-38 will conclude in FH126 & that an IND filing can be formally endorsed by the US FDA shortly thereafter, thus enabling commencement of Phase I CRD-38 testing in HFpEF by end-of-F2026 or perhaps early F2027. As shown in Exhibit 23, our model assumes comparable royalty revenue contribution from cannabidiol in either its orally-active or subcutaneiously-injectable forms in all three cardiovascular indications described above. But during the one-year time horizon to which our PT applies, we expect Phase III MAvERIC/recurrent pericarditis testing to dominate Cardiol's activities in the next

several quarters, & we expect capital market attention to be squarely focused on timelines to generating pivotal recurrence/NRS pain data in that indication.

- If indeed CardiolRx can demonstrate symptom mitigation in patients no longer sustained on chronic rilonacept/ Arcalyst therapy, we believe that CardiolRx can become an attractive standard-of-care in a recurrent pericarditis medical market currently dominated by Arcalyst (innovator Kiniksa Pharmaceuticals [KNSA-Q, NR] reported FQ325 sales of US$180.9M). Unsurprisingly, Kiniksa is as focused on recurrent pericarditis as Cardiol is & is expanding its own clinical activities in that space with a novel anti-interleukin-1 mAb KPL-387, for which a 165-patient Phase II recurrent pericarditis trial is ongoing & expected to generate interim data by mid-F2026.

Exhibit 23. Income Statement & Financial Forecast Data for Cardiol Therapeutics

Year-end December 31 (C$000, exc per share data)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
CardiolRx (Acute Myocarditis)	$0	$0	$0	$0	$0	$33,573	$84,436	$101,932	$136,724	$171,931
CardiolRx (Recurrent Pericarditis)	$0	$0	$0	$32,597	$81,981	$107,214	$116,154	$125,198	$125,949	$126,705
CardiolRx (injectable, diast HF)	$0	$0	$0	$0	$0	$42,954	$86,424	$108,678	$131,196	$153,981
CardiolRx (COVID-19)	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total revenue	**$0**	**$0**	**$0**	**$32,597**	**$81,981**	**$183,742**	**$287,015**	**$335,807**	**$393,869**	**$452,616**
Revenue growth (%)	*NA*	*NA*	*NA*	*NA*	*252%*	*224%*	*156%*	*117%*	*117%*	*115%*
R&D, clinical expenses	$7,500	$5,000	$5,123	$5,248	$5,377	$5,508	$5,643	$5,782	$5,923	$6,068
G&A, marketing expenses	$16,041	$15,765	$15,495	$16,537	$17,847	$20,240	$21,660	$20,964	$21,894	$22,843
Other expenses	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
EBITDA	**($23,541)**	**($20,765)**	**($20,618)**	**$10,812**	**$58,757**	**$157,993**	**$259,711**	**$309,062**	**$366,052**	**$423,704**
EBITDA growth (%)	(5%)	(12%)	(1%)	(152%)	443%	169%	64%	19%	18%	16%
EBITDA margin (%)	*NA*	*NA*	*NA*	*33%*	*72%*	*86%*	*90%*	*92%*	*93%*	*94%*
Non-operating expenses	$719	$719	$719	$719	$719	$719	$719	$719	$719	$719
EBIT	**($24,260)**	**($21,484)**	**($21,337)**	**$10,093**	**$58,038**	**$157,274**	**$258,992**	**$308,343**	**$365,333**	**$422,985**
Other non-oper expenses	$384	$384	$384	$384	$384	$384	$384	$384	$384	$384
EBT	**($24,643)**	**($21,867)**	**($21,721)**	**$9,709**	**$57,655**	**$156,891**	**$258,609**	**$307,960**	**$364,950**	**$422,602**
Tax expense	$0	$0	$0	$2,913	$17,296	$47,067	$77,583	$92,388	$109,485	$126,781
Net income, fully-taxed	($24,643)	($21,867)	($21,721)	$6,796	$40,358	$109,823	$181,026	$215,572	$255,465	$295,821
Fully-taxed EPS (basic)	($0.26)	($0.23)	($0.23)	$0.07	$0.43	$1.17	$1.93	$2.29	$2.72	$3.15
Fully-taxed EPS (fd)	**($0.23)**	**($0.20)**	**($0.20)**	**$0.06**	**$0.38**	**$1.03**	**$1.69**	**$2.02**	**$2.39**	**$2.77**
P/E (basic)	*NA*	*NA*	*NA*	*22.2x*	*3.7x*	*1.4x*	*0.8x*	*0.7x*	*0.6x*	*0.5x*
EV/EBITDA	*NA*	*NA*	*NA*	*9.7x*	*1.8x*	*0.7x*	*0.4x*	*0.3x*	*0.3x*	*0.2x*
S/O, basic (M)	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*	*94,009*
S/O, fd (M)	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*	*106,928*

Source: Cardiol Therapeutics financial filings; Leede Financial

- As summarized in Exhibit 24, our CRDL valuation is based on NPV (25% discount rate) & multiples of our F2031 EBITDA/EPS forecasts of $158.0M & $1.03/shr, respectively. Our EV calculation is based on pro forma cash of $27.6M (FQ325 balance sheet cash of $11.6M, plus US$11.4M/C$16.0M gross proceeds from the firm's Oct/25 equity offering) & no LT debt, & on fd S/O after considering new shares issued in the aforementioned equity offering of 106.9M. There is no denying that CRDL market value has equilibrated at trough levels in recent quarters & deploying capital into secondary indications to which we no longer ascribe value (specifically for cardiovascular side effects arising from COVID-19 infection as once tested in the LANCER trial) did not help, but we believe that capital markets will focus now on achievable milestones in recurrent pericarditis & heart failure that if favorable could establish CardiolRx/CRD-38 as seminal well-tested cardiovascular-targeted therapies.

Exhibit 24. Valuation Scenarios for Cardiol Therapeutics

NPV, discount rate		10%	20%	25%	30%	40%	50%
Implied value per share		$22.22	$9.99	**$6.87**	$4.78	$2.67	$1.20
Price/earnings multiple, 2031E		**10%**	**20%**	**25%**	**30%**	**40%**	**50%**
Implied share price[1]	**10**	$7.02	$4.95	$4.21	$3.60	$2.39	$2.03
	20	$14.04	$9.90	**$6.73**	$7.20	$4.78	$4.06
	30	$21.06	$14.85	$12.63	$10.80	$7.17	$6.09
EV/EBITDA multiple, 2031E		**5x**	**10x**	**12.5x**	**15x**	**17.5x**	**20x**
Implied share price[1,2]		$2.92	$5.95	**$7.46**	$8.97	$10.49	$12.00
One-year Cardiol target price (C$) [1]				**$7.02**			

[1] *Based on F2031 fd fully-taxed EPS of $1.03; EBITDA of $158.0M, discounted at 25%, FD S/O of 106.9M, including Oct/25 equity offering*

[2] *Includes pro forma cash $27.6M (FQ325 cash of $11.6M, plus US$11.4M/C$16.0M gross proceeds from Oct/25 equity offering; no LT debt*

Source: Cardiol Therapeutics financial filings; Leede Financial

- **Oncolytics Biotech (ONCY-Q, Buy, PT C$5.25/US$4.00).** AB/CA-based cancer-focused biologics developer Oncolytics Biotech continues to feature its reovirus formulation pelareorep in its oncology portfolio, with a recent recalibration in clinical priorities shifting the firm's focus away from HER2-negative/hormone receptor-positive metastatic breast cancer that had been targeted in Phase II testing in the firm's now-completed AWARE-1 & BRACELET-1 trials & toward targeting advanced pancreatic cancer as a lead indication.

Exhibit 25. Income Statement & Financial Forecast Data for Oncolytics Biotech

Year-end December 31											
(C$M, except per share data)	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
Pelareorep royalty revenue, by indication											
Breast cancer	$0.0	$0.0	$0.0	$0.0	$0.0	$24.1	$122.6	$250.1	$331.6	$416.2	$504.2
Pancreatic cancer	$0.0	$0.0	$0.0	$0.0	$6.6	$33.3	$67.5	$89.4	$112.2	$135.9	$160.4
Royalty rev, pelareorep	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$6.6**	**$57.3**	**$190.1**	**$339.5**	**$443.8**	**$552.1**	**$664.6**
Revenue growth (%)	*NA*	*NA*	*NA*	*NA*	*NA*	*767%*	*231%*	*79%*	*31%*	*24%*	*20%*
SG&A expense (amortization-adj)	$19.2	$25.0	$25.0	$25.0	$25.0	$25.0	$20.0	$17.5	$15.0	$12.5	$10.0
R&D expense	$8.0	$9.0	$11.2	$12.8	$14.7	$17.0	$19.5	$22.4	$25.8	$29.7	$34.1
EBITDA	**($27.2)**	**($34.0)**	**($31.2)**	**($30.3)**	**($25.6)**	**$22.9**	**$158.1**	**$307.0**	**$410.5**	**$517.4**	**$628.0**
EBITDA growth (%)	*NA*	*NA*	*NA*	*NA*	*NA*	*NA*	*690.5%*	*194.2%*	*133.7%*	*126.1%*	*121.4%*
EBITDA margin (%)	*NA*	*NA*	*NA*	*NA*	*NA*	*39.9%*	*83.2%*	*90.4%*	*92.5%*	*93.7%*	*94.5%*
Cumulative non-cash expenses	$7.3	$4.7	$3.2	$3.2	$3.2	$8.9	$42.7	$80.0	$105.8	$132.6	$160.2
Net Income, fully-taxed	($34.5)	($38.7)	($34.4)	($33.5)	($28.8)	$14.0	$115.4	$227.1	$304.6	$384.9	$467.8
EPS (fully-taxed, basic)	($0.33)	($0.37)	($0.33)	($0.32)	($0.28)	$0.13	$1.11	$2.19	$2.94	$3.71	$4.51
EPS (fully-taxed, fd)	**($0.29)**	**($0.32)**	**($0.28)**	**($0.28)**	**($0.24)**	**$0.12**	**$0.96**	**$1.88**	**$2.53**	**$3.19**	**$3.88**
S/O (basic, M)	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*	*103.6*
S/O (fully-diluted, M)	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*	*120.5*
P/E	*NA*	*NA*	*NA*	*NA*	*NA*	*8.3x*	*1.0x*	*0.5x*	*0.4x*	*0.3x*	*0.2x*
EV/EBITDA	*NA*	*NA*	*NA*	*NA*	*NA*	*4.0x*	*0.6x*	*0.3x*	*0.2x*	*0.2x*	*0.1x*
Key financial metrics in US$M, except EPS data											
Royalty rev, pelareo (US$M)	***$0.0***	***$0.0***	***$0.0***	***$0.0***	***$4.8***	***$41.5***	***$137.6***	***$245.7***	***$321.2***	***$399.7***	***$481.1***
EBITDA (US$M)	***($19.7)***	***($24.6)***	***($22.5)***	***($22.0)***	***($18.6)***	***$16.6***	***$114.4***	***$222.3***	***$297.1***	***$374.6***	***$454.6***
EPS, fd (US$)	***($0.21)***	***($0.23)***	***($0.21)***	***($0.20)***	***($0.17)***	***$0.08***	***$0.69***	***$1.36***	***$1.83***	***$2.31***	***$2.81***

Source: Oncolytics Biotech financial filings; Leede Financial

- Late last year, Oncolytics received feedback from the US FDA on pivotal study design for testing pelareorep in advanced pancreatic cancer, with Oncolytics indicating in a Nov/25 press release that a pivotal pancreatic cancer trial will likely target newly-diagnosed first-line patients & be comprised of three distinct study arms, one of which would treat patients with standard-of-care already-approved pancreatic cancer-targeted agents (specifically Eli Lilly's [LLY-NY, NR] nucleoside analog gemcitabine/Gemzar & Bristol Myers-Squibb's [BMY-NY, NR] albumin nanoparticle-based formulation nab-paclitaxel/Abraxane, originally developed by CA-based Abraxis Biosciences), another arm incorporating these agents plus pelareorep & a third arm incorporating all of these agents plus a checkpoint inhibitor of some type, probably either Roche's [ROG-SW, NR] anti-PD-L1 mAb atezolizumab/Tecentriq or Merck's [MRK-NY, NR] anti-PD1 mAb pembrolizumab/Keytruda, for which Oncolytics already has clinical data in other indications (breast cancer, specifically).

- Endpoints will be conventional, with overall survival likely to be the primary endpoint in the trial & CT-confirmed progression-free survival & overall response rate serving as key secondary endpoints. We summarized pelareorep's clinical history in pancreatic cancer in our Nov/25 ONCY report & will not repeat that analysis here other than to say that pelareorep generated positive clinical signals in at least five distinct Phase II studies, including the ongoing 55-patient GOBLET study from which response rate/survival data for pancreatic cancer specifically were reported at the 2025 ASCO conference, & all Phase II pancreatic cancer data are already published in peer-reviewed format.

- For now, metastatic breast cancer is expected to take a back-seat to advanced pancreatic cancer in Oncolytics' clinical portfolio; we expect Phase III pancreatic cancer testing to commence during FH126, pending availability of capital resources (the firm had US$8.8M in cash at the end of FQ325). As summarized in Exhibit 26, we base our ONCY valuation on pelareorep royalty revenue projections derived from two flagship indications, with new emphasis on pancreatic cancer as a lead indication & secondary emphasis on HER2-negative/hormone receptor-positive metastatic breast cancer for which Oncolytics has a comparably robust suite of Phase II clinical data but with competitive landscape justifying the prioritization of pancreatic cancer as a lead pelareorep indication in our view. Our valuation is still based on NPV (35% discount rate that will become increasingly conservative as pelareorep becomes an actively-tested Phase III-stage clinical asset) & multiples of our F2031 EBITDA/EPS forecasts.

Exhibit 26. Valuation Scenarios for Oncolytics Biotech

NPV, discount rate		20%	30%	35%	40%	50%	60%
Implied value per share		$16.82	$7.38	**$5.00**	$3.42	$1.59	$0.68
				Discounted share price end-of-2026			
Price/earnings multiple, F2031	**P/E**	**20%**	**30%**	**35%**	**40%**	**50%**	**60%**
Implied share price[1]	10	$4.62	$3.35	$2.88	$2.49	$1.89	$1.46
	20	$9.24	$6.70	**$5.76**	$4.98	$3.78	$2.92
	30	$13.86	$10.05	$8.64	$7.47	$5.67	$4.38
EV/EBITDA multiple, F2031		**5x**	**7x**	**8x**	**9x**	**10x**	**12x**
Implied share price[1,2]		$3.65	$5.09	**$5.81**	$6.53	$7.25	$8.69
One-year ONC target price (C$)				**$5.53**			
One-year ONC target price (US$)				**$4.00**			

[1] *Based on F2031 fd fully-taxed EPS forecast of $0.96; EBITDA of $158.1M; 35% discount rate*

[2] *EV based on FQ325 cash of $12.4M/US$8.8M, no LT debt, S/O (fd) of 120.5M (basic S/O 103.6M)*

[3] *PT derived from projections in CDN, converted to USD using USD:CDN ratio of 1.38x*

Source: Oncolytics Biotech financial filings; Leede Financial

- **ProMIS Neurosciences (PMN-Q, Spec Buy, PT US$9.50).** Our investment thesis for MA-based ProMIS Neurosciences assumes that the firm will focus its R&D efforts on its 144-patient Phase Ib PRECISE-AD trial, testing its beta-amyloid oligomer-targeted mAb PMN310 in patients with mild-to-moderate Alzheimer's disease. Interim impact on cognition will be assessed both at six- & twelve-month follow-up that is scheduled to transpire during FQ226 & FQ426, respectively. Both timelines are on pace to be achieved since ProMIS announced that the trial was fully-enrolled by mid-Dec/25.

ProMIS had US$15.7M in cash on the balance sheet at the end of FQ325, with supplemental capital available through future exercise of warrants infused into a multi-warrant equity offering that the firm consummated back in Jul/24; accordingly, we believe that the firm has sufficient cash resources to fund PRECISE-AD to data.

- As we described in our original report, ProMIS' portfolio of mAbs that target conformational epitopes found within disease-associated misfolded proteins, of which beta-amyloid oligomers are one, are all based on techniques innovated by the firm's current CSO & former University of British Columbia researcher Neil Cashman, whereby cyclic peptides mimicking epitopes that are only exposed when specified protein biomarkers are misfolded in some way, compromising their normal physiological function that in so doing confers symptoms associated with the disease in question. As shown in Exhibit 27, the pipeline includes PMN267 targeting misfolded TDP-43 in amyotrophic lateral sclerosis (ALS) & PMN442 targeting misfolded alpha-synuclein in Parkinson's disease or multiple system atrophy, both of which have been fully-humanized from the mouse-based hybridomas from which they were derived & are undergoing IND-enabling preclinical studies.
- Our model does ascribe market value & royalty revenue projections to both mAbs in their respective indications but as a practical matter, we do expect ProMIS to deploy existing capital toward driving PMN310 development in the PRECISE-AD trial. A trial of this size & study duration is unlikely in our view to provide statistically significant evidence of cognitive improvement (pivotal Phase III testing for Eisai's [4523-JP, NR] lecanemab was based on eighteen-month follow-up & from far more patients [1,795] to generate approvable impact on cognition in the CLARITY-AD trial, as published in Nov/22 in the *New England Journal of Medicine*) & ProMIS effectively acknowledged this reality when it featured the utility of interim quantification of phosphorylated tau protein as an early predictor of cognitive improvement in a study that it published in Dec/25 in the journal *Alzheimer's & Dementia*. Though it seems likely to us that capital markets could respond cautiously to interim biomarker data when presented by ProMIS in FQ226, we agree with the conclusions in the ProMIS biomarker study that any shifts in phosphorylated tau levels observed at interim analysis could indeed be a positive predictor or cognition signals that could be apparent (if not quite statistically significant) at final one-year analysis.

Exhibit 27. Development Pipeline for ProMIS Neurosciences

Asset	Target protein	Disease indication	Normal physiological role	Stage					Timelines to next milestone
				Discovery	Preclinical	I	II	III	
Lead antibodies in formal preclinical/IND-enabling testing									
PMN310	Epitope exposed in beta-amyloid oligomers	Alzheimer's disease	Synaptic plasticity, memory formation in hippocampus						Phase I completed, data in FH224 PRECISE-AD is active; data in FH226
PMN267	TDP-43 (Transactive response DNA-bind protein)	Amyotrophic lateral sclerosis (ALS)	Transcription factor (mRNA homeoasis/processing)						Complete IND-enabling studies, FH225 Commence Phase I ALS trial, FQ127
PMN442	Alpha-synuclein (pre-synaptic tetramer in the brain)	Parkinson's disease, multiple system atrophy	Controls neurotransmitter release, vesicle transport						Complete IND-enabling studies, FH225 Commence Phase I PD/MSA trial, FQ127
Misfolded protein antigens being targeted in discovery									
TBD	RACK1, SOD1	Amyotrophic lateral sclerosis (ALS)	Protein synthesis						Lead mAb generation by F2026
TBD	Tau	Alzheimer's disease Frontotemporal lobar degeneration (FTLD)	Microtubule stabilization neuron generation						Lead mAb generation by F2026
TBD	DISC1	Schizophrenia	Neuron generation mitochondrial transport						Lead mAb generation by F2026
TBD	Beta-amyloid vaccine	Alzheimer's disease prevention	Synaptic plasticity, memory formation in hippocampus						Lead mAb generation by F2026

Source: ProMIS Neurosciences; Leede Financial

- ProMIS' enterprise value is clearly established by capital markets at trough levels, perhaps based on market caution on the utility of targeting beta-amyloid oligomers as a way to mitigate Alzheimer's disease symptoms. There are currently no FDA-approved mAbs that selectively target beta amyloid oligomers (lecanemab & Eli Lilly's [LLY-NY, NR] donanemab do bind to oligomers, just not as selectively as PMN310 does), but the unique neurotoxicity conferred by beta-amyloid oligomers is actually well-documented in the medical literature & not just by ProMIS, nor

by its MA-based peer Acumen Pharmaceuticals (ACOS-Q, NR) that is developing its own oligomer-targeted mAb in ACU193.

- We have long considered the population genetics study published in 2008 in the journal *Annals of Neurology* by Osaka City University-based researchers, in which patients harboring unique mutations in the gene encoding beta-amyloid that lead to formation of beta-amyloid oligomers but no other higher-order amyloid forms (so no plaques or filaments) & yet patients still exhibited cognitive impairment identical to that observed in Alzheimer's disease patients. Through characterization of these oligomer-associated mutations, it became clear that oligomers are themselves neurotoxic & elimination of them could thus be relevant to mitigating cognitive impairment. PRECISE-AD data will be highly informative on this thesis, though obviously with direct insight into PMN310's prospects in this indication.

- **Quipt Home Medical (QIPT-T, Tender, PT NA).** As we described in our Dec/25 QIPT report, the firm is poised to be acquired by two investment firms, CA-based Kingswood Capital Management & AL-based Forager Capital Management, in a deal valuing the firm at US$3.65/shr.

  - This price level implies that QIPT is being valued by its acquirers at an EV of US$257.6M when considering the firm's FQ425 balance sheet data (cash of US$12.9M, LT debt of US$86.6M) & fd S/O of 50.4M. This valuation corresponds to an EV-to-FQ425 EBITDA run-rate ratio of 4.3x & an EV-to-T12M EBITDA ratio of 4.6x, with both multiples interestingly being quite comparable to the average EBITDA multiple that Quipt itself ascribed to its own acquisitions (4.7x), as consummated during our coverage history of the firm.

  - QIPT shares closed at US$3.56/shr during the last trading session prior to our publication of our Weekly, so there remains a modest price discrepancy between QIPT's current market value & its eventual take-out value that investors may wish to exploit at their discretion. We are maintaining our recommendation of Tender to the Kingswood/Forager offer, based on our expectation at the time of the bid announcement that QIPT as a practical exercise was unlikely to achieve a price level approximating bid value without the impetus of the bid itself driving it to that level. We expect the transaction to close during H126, before which Quipt may report another quarter of financial data (FQ126 data for the Dec/25-end quarter), & for QIPT to depart from our official coverage thereafter.

- **Appili Therapeutics (APLI-T, Under Review).** Our valuation for NS-based infectious disease-focused drug developer Appili Therapeutics was originally based in part on the firm's Phase III development activities for the RNA polymerase inhibiting drug favipiravir, for which disappointing anti-retroviral data were generated in Nov/21 from the 1,231-patient PRESECO trial.

  - Our investment thesis for the firm was correspondingly cautious on other pipeline priorities & on the firm's ability to fund development activities for existing pipeline candidates, a pipeline that still includes a live attenuated tularemia vaccine ATI-1701 targeting *Francisella tularensis* infection & the topical paromomycin formulation ATI-1801 targeting cutaneous leishmaniasis, both of which are of interest to the US government for biodefense reasons & both of which could be eligible for priority review vouchers should Appili ever be able to fund either agent through to FDA approval.

  - The firm also has a taste-masked metronidazole formulation (ATI-1501/Likmez) that was FDA-approved in Sept/23 for treating trichomoniasis; it was launched by the firm's NY-based commercial partner Saptalis Pharmaceuticals (private) in May/25, but Saptalis has not put any initial Rx sales data into the public domain for us to review. In its FQ226 financial update in Nov/25, Appili indicated that Likmez sales were growing admittedly with only about five months of sales data available to that timepoint.

  - Appili closed on a modestly-sized tranche of a non-brokered equity offering in Dec/25, but the magnitude of new capital (just under $0.2M, added to the firm's FQ226 cash of $0.35M) is insufficient to fund clinical drug development to any substantive degree. The firm has a non-trivial amount of total debt on its balance sheet of $12.2M & accounts payable of $4.1M at the end of the Sept-end FQ226 period. But the firm has access to other sources of capital, mostly from US government sources for which applications are pending, to fund ATI-1701 or ATI-1801 (or both) Phase II/III clinical testing. A pivotal ATI-1701 trial (which would be focused on testing the vaccine's ability to mitigate Francisella tularensis infection in animal models) is already partially funded by a US$11.6M alliance with the US Air Force.

- A new clinical program focused on targeting multidrug-resistant *Candida* infections is being driven forward in partnership with the private firm Vitalex to develop a dual-antigen vaccine VXV-01, based on a formulation of surface antigens from *Candida albicans* called Als3 & Hyr1; a five-year US$40M award from the US National Institute of Allergy & Infectious Disease is in place to develop this asset, for which Appili now has exclusive worldwide rights should VXV-01 ever be FDA approved.
- Appili's infectious disease pipeline is attractive in our view, but its balance sheet is not, even before considering new capital from the US NIAID to fund VXV-01 development. But we will continue to monitor pipeline progress to the limits of Appili's capital resources while monitoring competitive landscape for the infectious disease medical markets to which each therapy applies.

Other Healthcare News That Caught Our Eye This Week

- **Insilico Medicine (3696.HK, NR) Pharma.AI platform attracts another drug discovery partnership.** Servier Group (France, private) signed a multi-year oncology collaboration valued at up to $888M, with Insilico receiving approximately $32M in upfront and near-term R&D payments. Like many AI discovery platform deals, economics remain heavily weighted toward developmental and commercial milestones, with upfront payments representing 2-5% of total deal value. The Servier agreement follows this pattern at 3.6% front-loaded economics, comparable to Insilico's November 2022 Sanofi deal ($21.5M upfront on $1.2B total, 1.8%).
  - Other major 2025 platform deals have included a formal Eli Lilly collaboration (versus previous software licensing) valued at over $100M (November 2025). During H1 2025 alone, Insilico's company materials claim 61 partnerships with clients for software licensing and services. The Servier Group deal comes immediately after Insilico completed the largest biotech IPO in Hong Kong for 2025, raising HKD 2.277 billion ($292M USD) on December 29, 2025. The company's market cap now (as of Jan 7th) sits at HK$22.57B, approximately $2.9B US.
  - Of note, AI biotech companies like Insilico with recurring software and platform licensing revenue are commanding EV/Revenue multiples of 20x-30x, similar to higher-growth SaaS companies rather than traditional clinical-stage biotechs. This valuation approach, supported by recent Pitchbook Analyst Note (Nov/25) showing AI-native biotechs commanding a 45% valuation premium over traditional biopharma, rewards scalable platform revenue streams and reduced regulatory risk compared to binary drug development outcomes
  - The Insilico-Servier partnership validates accelerating interest in compressing drug discovery timelines through AI, a relevant thesis for Rakovina Therapeutics (RKV-V, NR), previously covered in our weekly series. Both companies leverage AI to compress discovery timelines, but their business models diverge. While Insilico operates a dual-revenue model licensing its proprietary Pharma.AI platform to partners alongside internal development, Rakovina licenses third-party AI platforms (Variational AI's Enki, UBC's Deep Docking) with target-specific exclusivity for DDR kinases and DNA-damage response pathways, concentrating all value in wholly-owned programs.
  - The company's lead programs include kt-5000 ATR inhibitors engineered for CNS penetration in treatment-resistant brain cancers and PARP1-selective inhibitors designed to cross the blood-brain barrier for CNS malignancies. This approach means Rakovina will not engage in the two-to-three year platform monetization cycle inherent to discovery partnerships but retains full ownership economics for candidates while bearing development risk until potential later-stage partnering opportunities. Rakovina expanded its collaboration with Variational AI earlier this week, ostensibly to further accelerate lead optimization of multiple kt-5000 ATR inhibitor candidates that have demonstrated preclinical validation, including superior PK and CNS penetration versus existing clinical-stage comparators. The refinement focuses on enhancing potency, selectivity, and CNS penetration to expedite clinical candidate selection.
- **Amgen (AMGN-Q, NR) acquires Dark Blue Therapeutics (Private) for up to $840 million, centered on lead asset DBT 3757, a first-in-class targeted protein degrader for acute myeloid leukemia**. Announced January 6, the acquisition brings DBT 3757 into Amgen's oncology portfolio, currently in preclinical IND-enabling studies. The deal structure includes an undisclosed upfront payment plus milestones reaching $840 million total, marking Amgen's first M&A since the $27.8 billion Horizon Therapeutics acquisition in 2023. DBT 3757 works by eliminating (degrading rather than just blocking) two proteins called MLLT1 and MLLT3 that leukemia cells need to survive and grow.

- The primary patient population is KMT2A-rearranged AML, where a genetic abnormality creates defective fusion proteins involving MLLT1 or MLLT3 that drive cancer growth. This adverse-risk subset represents 3-10% of adult AML cases and has poor outcomes with standard chemotherapy alone. Preclinical data from the December 2024 American Society of Hematology meeting showed strong activity in KMT2A-rearranged leukemia models and broader activity in NPM1-mutated AML (a separate genetic subtype representing ~30% of cases), suggesting potential applicability beyond the initial KMT2A-rearranged population.
- An initial development path could target relapsed/refractory AML patients, particularly those who stop responding to recently approved menin inhibitors (revumenib approved November 2024 for the same KMT2A-rearranged and NPM1-mutated patient populations). DBT 3757 maintained activity in lab models where menin inhibitors lost effectiveness due to resistance mutations, positioning it as a potential therapy after menin inhibitor failure. Another development pathway could include using DBT 3757 to maintain remissions in patients waiting for bone marrow transplants, supported by preclinical safety data showing no harm to normal blood cell production.
- This development holds positive implications for our coverage of Medexus (MDP-T, Buy, PT C$8.00). New AML therapies generally expand the transplant market rather than replace it. In the venetoclax PARADIGM trial, transplant rates improved from 40% to 60%, getting more patients into remission in condition sufficient to undergo transplant. DBT 3757's target patients (KMT2A-rearranged and NPM1-mutated AML) require bone marrow transplant as the only curative treatment option, creating demand for conditioning chemotherapy like GRAFAPEX (treosulfan-fludarabine) administered immediately before transplant to prepare patients for donor cells. GRAFAPEX secured FDA approval in January 2025, with Medexus generating $6.2 million in revenue during the six-month period ended September 30, 2025 (fiscal Q1+Q2 2026). Medexus continues to expect that annual product-level net revenue from GRAFAPEX will exceed US$100 million within five years after commercial launch.

Capital Markets Summary

Exhibit 28. EBITDA Or EPS-Positive Canadian Healthcare Stocks

Company	Filing Curr.	Sym.	Shrs Out. (M)	Share Price 7-Jan	Mkt Cap (M)	Mkt Cap (C$M)	Ent. Value (M)	Ent. Value (C$M)	EV/EBITDA (T12M)	EV/EBITDA FY1	EV/EBITDA FY2	Price/Earnings (T12M)	Price/Earnings FY1	Price/Earnings FY2
Profitable Canadian healthcare firms - specialty services [2]														
dentalcorp Holdings	CAD	DNTL	191.5	$10.94	2,095	2,095	3,429	3,429	12.0x	10.7x	9.6x	NA	20.5x	18.7x
DRI Healthcare Trust	CAD	DHT.UN	55.1	$15.72	866	866	1,281	1,281	8.3x	5.7x	5.7x	NA	7.7x	6.9x
Jamieson Wellness	CAD	JWEL	41.7	$34.25	1,427	1,427	1,866	1,866	13.0x	11.7x	10.2x	22.9x	18.4x	14.7x
K-Bro Linen	CAD	KBL	13.0	$34.90	453	453	754	754	8.5x	7.8x	7.0x	20.9x	17.7x	15.2x
Medical Facilities [1]	CAD	DR	18.0	$11.70	210	291	397	549	6.9x	5.6x	5.8x	7.6x	10.3x	9.7x
Microbix Biosystems	CAD	MBX	139.0	$0.25	34	34	29	29	NA	NA	NA	NA	NA	NA
Savaria	CAD	SIS	71.6	$23.20	1,662	1,662	1,868	1,868	10.7x	10.3x	9.3x	26.8x	19.8x	17.1x
Profitable Canadian healthcare firms - specialty pharmaceuticals development/sales [2]														
Aurinia Pharmaceuticals	USD	AUPH	131.8	$15.44	2,036	2,812	1,756	2,426	11.9x	8.6x	8.0x	26.8x	20.1x	16.5x
Bausch Health	USD	BHC	370.9	$7.63	2,830	3,909	32,453	44,830	9.8x	8.9x	8.6x	7.8x	2.0x	1.8x
BioSyent	CAD	RX	11.5	$12.56	144	144	122	122	8.5x	9.8x	9.7x	16.4x	17.0x	14.4x
Cipher Pharmaceuticals [1]	CAD	CPH	25.4	$10.63	270	373	380	524	19.1x	14.9x	16.4x	15.7x	15.3x	27.3x
HLS Therapeutics	CAD	HLS	31.3	$4.79	150	150	210	210	9.4x	7.9x	6.6x	NA	NA	NA
Knight Therapeutics	CAD	GUD	99.3	$5.90	586	586	574	574	11.1x	9.5x	8.8x	NA	NA	NA
Medexus Pharmaceuticals	CAD	MDP	32.4	$2.98	97	97	113	113	5.4x	3.9x	6.0x	NA	54.6x	NA
Profitable Canadian healthcare firms - specialty pharmaceuticals development/sales														
CareRx	CAD	CRRX	62.8	$3.89	244	244	311	311	11.1x	9.5x	7.9x	NA	57.8x	20.3x
Chartwell Retirement Residences	CAD	CSH.UN	310.5	$20.30	6,303	6,303	8,886	8,886	23.8x	22.2x	18.1x	NA	NA	NA
Extendicare	CAD	EXE	94.5	$21.59	2,039	2,039	2,211	2,211	13.3x	13.1x	10.1x	20.0x	20.4x	18.6x
Northwest Healthcare Properties REIT	CAD	NWH.UN	250.0	$5.32	1,330	1,330	5,184	5,184	20.1x	21.4x	21.6x	26.6x	NA	NA
Nova Leap Health	CAD	NLH	87.3	$0.28	24	24	26	26	10.1x	NA	NA	31.6x	NA	NA
Sienna Senior Living	CAD	SIA	95.0	$21.01	1,997	1,997	3,226	3,226	22.6x	20.0x	16.4x	46.8x	43.8x	36.2x
Profitable Canadian healthcare firms - medical equipment distribution/sales														
Covalon Technologies	CAD	COV	27.6	$1.82	50	50	35	35	12.9x	20.5x	7.6x	24.2x	NA	15.2x
Quipt Home Medical [3]	USD	QIPT	43.4	$3.55	154	213	325	449	NA	5.9x	5.0x	NA	NA	NA
Viemed Healthcare	USD	VMD	38.0	$7.25	276	276	397	549	8.8x	6.5x	5.6x	20.8x	21.0x	15.4x
Profitable Canadian healthcare firms - medical equipment distribution/sales														
Healwell AI	CAD	AIDX	292.8	$0.85	249	249	326	326	NA	NA	34.6x	NA	NA	NA
Kneat.com	CAD	KSI	95.5	$5.00	478	660	448	448	NA	48.1x	27.1x	NA	NA	NA
Vitalhub	CAD	VHI	63.1	$9.02	569	787	447	447	20.5x	17.5x	13.2x	NA	NA	37.6x
Well Health	CAD	WELL	254.0	$4.17	1,059	1,059	1,755	1,755	16.9x	8.8x	8.4x	NA	13.5x	10.2x
Average									**12.8x**	**12.9x**	**11.5x**	**22.5x**	**22.5x**	**17.4x**
Recently-acquired Canadian healthcare firms														
Andlauer	*CAD*	*AND*	*39.2*	*$54.97*	*2,152*	*2,152*	*2,165*	*2,165*	*13.4x*	*NA*	*NA*	*32.0x*	*NA*	*NA*
Theratechnologies	*CAD*	*TH*	*46.0*	*$4.47*	*206*	*206*	*238*	*238*	*12.3x*	*NA*	*NA*	*NA*	*NA*	*NA*

[1] Share price converted to USD for stocks reporting financial data in USD but for which share value is reported in CAD; price refers to prior day close, EV calculations based on cash/LT debt reported in most recent quarter

[2] Legacy specialty pharmaceutical firm & coverage stock Theratechnologies (TH-T, THTX-Q) was acquired in Sept/25 by CB Biotechnology/Future Pak for cumulative consideration of US$4.20/shr; Andlauer's acquisition by UPS (UPS-NY, NR) is now closed as of Nov/25

[3] Quipt Home Medical was bid to be acquired by Kingswood Capital & Forager Capital for US$3.65/shr in Dec/25

Source: Refinitiv, company reports, Leede Financial

Exhibit 29. Trailing Four-Week, One-Year & Two-Year Relative Share Price Performance For EBITDA/EPS-Positive Canadian Healthcare Equities – Specialty Services & Specialty Pharmaceutical Firms



Source: Refinitiv, company reports, Leede Financial

Exhibit 30. Trailing Four-Week, One-Year & Two-Year Relative Share Price Performance For EBITDA/EPS-Positive Canadian Healthcare Equities – Eldercare Services & Medical Technology Distribution/Healthcare IT Services



Source: Refinitiv, company reports, Leede Financial

Important Information and Legal Disclaimers

Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

Description of Disclosure Codes

1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th.
2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives.
3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months.
4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report.
5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months.
6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months.
7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company.
8. Leede acts as a market maker of the company.
9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer.
10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination

All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm's research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification

The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures

This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures

This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be affected through a U.S. broker-dealer.

Rating Definitions

Buy	The security represents attractive relative value and is expected to appreciate significantly from the current price over the next 12-month time horizon.
Speculative Buy	The security is considered a BUY but carries an above-average level of risk.
Hold	The security represents fair value and no material appreciation is expected over the next 12-month time horizon.
Sell	The security represents poor value and is expected to depreciate over the next 12-month time horizon.
Under Review	The rating is temporarily placed under review until further information is disclosed.
Tender	Leede Financial Inc. recommends that investors tender to an existing public offer for the securities in the absence of a superior competing offer.
Not Rated	Leede Financial Inc. does not provide research coverage of the relevant issuer.

Rating Distribution

RECOMMENDATION	NO. OF COMPANIES	%
Buy	9	56%
Speculative Buy	4	25%
Hold	1	6%
Sell	-	-
Tender	1	6%
Under Review	1	6%

Historical Target Price

Appili Therapeutics | APLI-TSXV	None
Cardiol Therapeutics | CRDL-TSX, NASDAQ	None
CareRx | CRRX-TSX	None
Cipher Pharmaceuticals | CPH-TSX	None
Eupraxia Pharmaceuticals | EPRX-TSX, NASDAQ	None
Extendicare | EXE-TSX	None
K-Bro Linen | KBL-TSX	4,5
Medexus Pharmaceuticals | MDP-TSX	4
Medical Facilities | DR-TSX	None
Nanalysis Scientific | NSCI-TSXV	None
Oncolytics Biotech | ONCY-NASDAQ	None
Perimeter Medical Imaging | PINK-TSXV	None
Profound Medical | PRN-TSX, PROF-NASDAQ	None
ProMIS Neurosciences | PMN-NASDAQ	2
Quipt Home Medical | QIPT-TSX, NASDAQ	None
Sernova Biotechnologies | SVA-TSX	2